Chitosan-based nanoparticles for siRNA-mediated downregulation of P-glycoprotein in rat brain endothelial cells in vitro by Auganes, Hanne
Biotechnology
May 2011
Kjell Morten Vårum, IBT
Sabina Strand, IBT
Submission date:
Supervisor:
Co-supervisor: 
Norwegian University of Science and Technology
Department of Biotechnology
Chitosan-based nanoparticles for
siRNA-mediated downregulation of P-
glycoprotein in rat brain endothelial
cells in vitro
Hanne Auganes

 Preface  
 
This Master of Science thesis in biotechnology was submitted to the institute of 
biotechnology belonging to the faculty of natural sciences at the Norwegian University of 
Science and Technology. The thesis was performed at facilities within the institute of physics 
in the time period September 2010 to April 2011. 
 
I would like to express my gratitude towards my supervisor Sabina P. Strand for guidance and 
discussions as well as motivation, Kjell M. Vårum for being available for questioning about 
chitosan and its chemistry. A special thank goes out to PhD student Jostein Malmo for his 
time and devotion to introduce me to the techniques used and help with planning the 
experiments.  
 
I would also like to thank my high school teacher in biology, Trond Herfindal who highly 
encouraged my ambitions to study biotechnology. Finally my family and all friends in the 
biotechnology class of  ’11 for support and feedback throughout the years.  
 
 
 
Trondheim, May 16
th
 
 
Hanne Auganes 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Abstract  
 
Chitosans are cationic polymers desirable for use in nucleic acid delivery due to its 
biocompability, biodegradable and low toxic nature. The P-glycoprotein (P-gp) pump is a 
member of membrane transporters in brain endothelial cells which recognizes xenobiotics, 
extruding them from the cells. P-gp is a highly clinically relevant target as it also limits 
accessibility of drugs from the blood to the brain. 
 
The overall aim of this work was to investigate the feasibility of using chitosan as a delivery 
vehicle for siRNA-mediated knockdown of P-glycoprotein (P-gp) efflux pump in an in vitro 
model of blood brain barrier. The human lung cancer cells (H1299) stably expressing GFP 
was used for screening and optimization of the delivery system and conditions. Lung cancer is 
often represented among multidrug resistant cell lines and is therefore also a suitable target 
for knockdown of transporters.  The main objective was to implement this knowledge to 
efficiently downregulate the P-gp pump residing in the rat brain endothelial cell line RBE4.   
 
The approach was to first establish suitable physiochemical characteristics of the chitosans 
like DPn and the N/P ratios of chitosan/siRNA complexes by studying exogenous GFP and 
endogenous GAPDH expression and uptake of fluorescently labeled siRNA by flow 
cytometry. Cytotoxicity profiling of the chitosans and polyplexes was preformed with 
AlamarBlue, PI-staining, Cell counting and BCA assay. We further investigated the effect of 
chitosan mediated mdr1a-siRNA on drug efflux in the RBE4 cells using two functional 
assays; Rhodamine 123 efflux by flow cytometry and visualization of the anticancer drug 
Doxorubicin by CLSM. 
 
We demonstrated that chitosan can be used as an efficent delivery vehicle for siRNA in both 
H1299 and RBE4 cells with negligible cytotoxicity in vitro. The formulated chitosan/siRNA 
polyplexes was found to dependent on DPn and N/P ratios in order to exert maximal effect on 
both uptake and knockdown. Specifically, we managed to downregulate the P-gp expression 
in RBE4 cells using chitosans with a high DPn complexed with mdr1a-siRNA in a low N/P 
ratio. Together these results elucidate the potential of chitosan mediated siRNA 
downregulation of the P-gp pump in RBE4 cells and further development for in vivo 
applications.  
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1. Introduction 
 
Chitosan is a cationic polymer and has been widely applied for pDNA delivery; there is 
however a limited amount of research preformed with chitosan/siRNA polyplexes. The use of 
chitosan in nucleic acid delivery is desirable because of its biocompatibility and low toxicity 
profile. Chitin and chitosan have been a part of a research program at the institute for 
biotechnology at NTNU for many years and in collaboration with the St.Olavs Hospital we 
wanted to target a clinical target with focus on the blood brain barrier. 
 
The P-gp pump is a member of membrane transporters in brain endothelial cells which 
recognizes xenobiotics, extruding them from the cells. P-gp is a highly clinically relevant 
target as it limits accessibility of drugs from the blood to the brain. Furthermore, 
overexpression of P-gp and other transporters in tumor cells is responsible for multidrug 
resistance in cancer. The pump is expressed by the mdr1 gene and downregulation of its 
expression can mediate drug accumulation in the cells. 
 
As the RBE4 cell line was not available at the start of this thesis, we started our work by 
screening of different chitosan/siRNA formulations in human lung cancer cells (H1299). This 
cell line stably express GFP and is therefore well suited for optimization of the delivery 
system and conditions. Besides, lung cancer is often represented among multidrug resistant 
cell lines and is therefore also a suitable target for knockdown of transporters. 
 
The overall aim of this work was to investigate the feasibility of using chitosan as a delivery 
vehicle for siRNA-mediated knockdown of P-gp efflux pump in an in vitro model of blood 
brain barrier. The approach was to first establish suitable physiochemical characteristics of the 
chitosans like DPn and the N/P ratios of chitosan/siRNA complexes as well as cytotoxicity 
profiling. These preliminary studies were preformed with H1299 cells and the acquired 
knowledge was used with the RBE4 cells for further development. 
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2. Theory  
2.1 RNA interference (RNAi) 
 
RNAi interference is a part of the body’s own defense machinery against unwanted and 
potentially harmful mobile genetic elements like transposons and viruses (Elbashir et al. 
2001) . RNAi was first proposed in the nematode worm Caenorhabditis elegans  where they 
fund a potent and specific genetic interference after the introduction of double-stranded RNA 
(dsRNA) (Fire et al. 1998). A schematic of the RNAi mechanism including effects of 
introduced short hairpin RNA and synthetic siRNA is presented in figure 2.1. 
 
 
 
 
Figure 2.1 Shematics of the different RNA interference mechanisms (Martin and Caplen 2007). 
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Usually a large double-stranded RNA molecule is diced into small double-stranded siRNAs 
21-28 base pairs long by the enzyme Dicer. They then assemble with proteins into 
ribonucleoprotein particles where the small interfering RNA is unwound to produce an RNA-
Induced Silencing Complex (RISC) (Snustad and Simmons 2010). Argonaute 2, a 
multifunctional protein contained within RISC, unwinds the siRNA and leads to cleavage of 
the sense strand (or passenger strand) of the siRNA and further degradation (Matranga et al. 
2005). 
2.1.1 Short hairpin RNA (shRNA) and Small interfering RNA (siRNA) 
 
It is possible to exploit the RNAi pathway in one of two ways: either by using a viral vector to 
express short hairpin RNA (shRNA) that resembles micro- RNA precursors, or by introducing 
siRNAs ~22 nucleotides with 3’ OH dinucleotide overhangs that mimic the Dicer cleavage 
product into the cytoplasm (de Fougerolles et al. 2007).  
 
After delivery of shRNA expression vectors into the cytoplasm, the vector needs to be 
transported into the nucleus for transcription. The primary transcripts are processed by 
the enzyme Drosha to form pre shRNAs. Pre-shRNAs are transported to 
the cytoplasm via exportin 5, to be loaded onto the Dicer complex where they are further 
processed to mature shRNA. Mature shRNA in the Dicer complex are associated with the 
RISC and results in an RNA interference function either through mRNA cleavage and 
degradation, or through translational suppression (Rao et al. 2009). 
 
However, the smaller size of siRNA’s and the need for cytoplasmic delivery only together 
with ease of availability and efficiency makes the introduction of siRNA more amenable for 
RNAi. siRNA can be synthetically produced and then introduced into the cells cytoplasma, 
thereby bypassing Dicer mechanics (Whitehead et al. 2009).  
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This shortcut reduces the potential for an innate immune interferon response and the 
shutdown of cellular protein expression that can occur following the interaction of long 
dsRNA with intracellular RNA receptors(Grimm et al. 2006). The activated RISC targets a 
sequence in a messenger RNA that is complimentary to the interfering RNA.  If the sequences 
are perfectly base-paired, the mRNA is cleaved and the mRNA is degraded. (Snustad and 
Simmons 2010) The activated RISC–siRNA complex can then be recycled for the destruction 
of identical mRNA targets, it behaves as a catalyst.  
 
When using appropriately designed siRNA, the RNAi machinery can be exploited to silence 
nearly any gene in the body, giving it a broader therapeutic potential than typical small-
molecule drugs (Whitehead et al. 2009). The rest of this section will focus solely on siRNA 
delivery and its applications. 
2.1.3 The challenges and barriers of siRNA delivery  
 
In order for siRNA delivery to be efficient it must overcome several obstacles both outside 
and inside the cell. Because of its large size and negative charge, naked siRNA has a low 
ability to cross cell membranes. Thus, it must be complexed with a sufficient nanoparticle 
carrier which should express all of the qualities expected from an optimal delivery agent.  
 
Bioconjugation of siRNAs with lipids and polymers is desirable in order to increase their 
thermodynamic and nuclease stability, improve the biodistribution and pharmacokinetic 
profiles of siRNAs, and target them to specific cell types. Although transfection efficiency of 
siRNAs into cultured cells is satisfactory for most in vitro applications, its therapeutic 
applications in vivo is more challenging (De Paula et al. 2007). Ideally, a delivery mechanism 
should;  
 
1) Be capable of binding siRNAs in a reversible manner to ensure subsequent release of the 
siRNAs in target cells.  
2) Protect siRNAs from nuclease degradation during transit through the circulation.  
3) Efficiently escape from endosomal compartment.  
4) Be biocompatible and biodegradable  
5) Avoid rapid clearance by the liver and kidney. 
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Some of the limitations and obstacles of siRNA delivery are presented in figure 2.2.  
 
 
 
 
Figure 2.2 The limitations to siRNA delivery and the siRNA-induced RNAi pathway: (A) siRNA 
stability, (B) siRNA nanoparticle stability, (C) siRNA or siRNA nanoparticle targeting and 
internalization, (D) siRNA endosomal escape, and (E) siRNA off-target effects (Tokatlian and 
Segura 2010). 
 
a) Interaction between nucleic acids and cationic lipids or polymers 
 
Complex formation relies on the electrostatic interaction between the negatively charged 
nucleic acid and the positively charged transfection reagent. The complex enhances nucleic 
acid uptake by compacting the size of the nucleic acid by a phenomenon called condensation 
(Bloomfield 1996). Cationic polymers differ from cationic lipids in that they do not contain a 
hydrophobic moiety and are completely soluble in water (Elouahabi and Ruysschaert 2005). 
Compared with cationic liposomes, they have the advantage of compressing DNA molecules 
to a relatively small size (Gershon et al. 1993; Ruponen et al. 1999). This can be crucial for 
gene transfer, as small particle size may be favorable for improving transfection efficiency 
(Lv et al. 2006).  
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b) Cellular binding 
 
There are several ways the siRNA delivery agents make contact with the cells; some are 
receptor mediated while other relies merely on electrostatic interactions. The surface charge 
of the delivery vehicle is an important property that affects their interaction with cells and 
non-cellular components. A charge acts as a double-edged sword, which aids cellular uptake 
but can also result in non-specific interactions with non-targets cells and extracellular 
components such as serum proteins and extracellular matrices. This lack of specificity is not a 
problem in culture when there is only one type of cell, but is a problem for systemic in vivo 
delivery (Wolff and Rozema 2007). 
 
c) Cellular uptake 
 
Most siRNA nanoparticles enter the cell through endocytosis, which poses a major limitation 
to siRNA efficiency as it must be released into the cytosol to activate the RNAi pathway. The 
best understood uptake pathway is clathrin-mediated endocytosis, molecules preferentially 
interact with generic complementary binding sites like lectin or charged interfaces (Khalil et 
al. 2006). Figure 2.3 illustrates the clatrin-mediated endosytosis which occurs constitutively in 
all mammalian cells. 
 
 
Figure 2.3 Clathrin-mediated endosytosis and pathway in the cell (Khalil et al. 2006). 
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In general, siRNA nanoparticles (in vitro) enter more than 90% of the cells through 
endocytosis; however, the release of the nanoparticles and/or siRNA to the cytosol occurs less 
readily (Tokatlian and Segura 2010). Nanoparticle capture within the endosomal–lysosomal 
pathway as a consequence of endocytosis is the predominant barrier for enabling interaction 
with cytoplasmic or nuclear targets. The inclusion of endosomal buffering and pH-activated 
polymers and membrane-interacting peptides capable of endosomal escape and transport to 
the cytosol are methods to overcome this (Howard et al. 2008). 
 
d) Endosomal escape  
 
If the siRNA nanocomplex is unable to exit the endosome, it will be trafficked through 
endomembrane compartments of decreasing pH and be subjected to degradative conditions in 
the lysosome.(Whitehead et al. 2009) The high charge density of cationic polymers allows 
them to escape from endosomes and deliver their nucleic acid cargo into the cytosol through 
the so-called “proton-sponge” effect. The polycationic nature of the polymer is thought to 
buffer low endosomal pH through enhanced influx of protons and water, resulting in 
endosome rupture (S. Akhtar and Benter 2007; Martinez et al. 2002). 
 
e) siRNA off-target effects 
 
It has been argued that off-target transcript silencing is siRNA sequence dependent and is a 
fundamental feature of RNAi-mediated silencing (Jackson et al. 2006). Imperfect pairing of 
siRNA strands with sequence motifs that reside primarily in 3′ UTR regions of cellular 
mRNAs can lead to microRNA-like off-target silencing (Jackson and Linsley 2010). They 
further suggested that many transcripts can be affected and it is inherent to any siRNA 
sequence, because only short regions of sequence complementarity are required for this type 
of off-target silencing.  
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Other off-target effects of siRNAs result from innate immune responses to either 
oligonucleotides or the delivery vehicles used to carry them to cells or tissues. Toll-like 
receptors (TLRs) protect the host from pathogens by detecting infectious non-self agents 
including double-stranded RNA (Jackson and Linsley 2010). Figure 2 shows some of the 
common siRNA off target effects. 
 
Figure 2.4 Types of off-target effects observed with siRNAs. TLR; toll-like receptor (Jackson 
and Linsley 2010). 
 
Ineffective siRNAs can lead to false negative conclusions, while non-specific siRNAs can 
produce false-positive conclusions concerning the role of the target gene in functional assays 
(Jackson and Linsley 2004). These limitations in siRNA delivery can be circumvented by 
modifying the introduced siRNA sequence. 
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2.2 Chitin and chitosan 
 
Chitin is a marine polysaccharide consider to be the second most abundant biomass resource 
after cellulose, and also the most unutilized (Kurita 2006). Chitosans are derived from chitin 
found in the exoskeleton of arthropods and in the cell wall of many fungi and is a family of 
cationic and linear polysaccharides. They are binary polysaccharides comprised of randomly 
distributed beta (1–4) linked 2-amino-2-deoxy-b-D glucose (GlcN; D-unit) and the N-
acetylated analogue (GlcNAc; A-unit) (Roberts 1992).  
2.2.1 Manufacturing of chitosan and its applications 
 
Chitosan is chemically produced from chitin by alkaline de-N-acetylation and the conditions 
used for deacetylation determines the polymer molecular weight and the fraction of acetylated 
units; FA (Dash et al. 2011). A schematic presentation of the deacetylation is presented in 
figure 2.3 
 
 
Figure 2.5 Shematic of the deacetylation of chitin to chitosan (Ravi Kumar 2000). 
 
The application potential of chitosan is vast, in food and nutrition industries, biotechnology, 
material science, drugs and pharmaceuticals, agriculture and environmental protection, and 
recently in gene therapy (Harish Prashanth and Tharanathan 2007). An important property for 
biological applications is that chitosans can interact with negatively charged mucin layers on 
mucosal tissues or cell membrane proteoglycans in a process called muco/bioadhesion (Issa et 
al. 2005).  
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Chitosans is considered biodegradable and breaks down slowly to harmless products which 
are absorbed by the human body. Moreover, chitosans are biocompatible and generally have a 
low toxicological profile when administered to the body. This is an important aspect in 
regards to the metabolic fate or biodegradation which could provide fragments suitable for 
renal clearance or general amino acid turnover in the body (Kean and Thanou 2010). Based 
on these properties, chitosan is rendered as a suitable and safe delivery vehicle for nucleic 
acids. 
2.2.2 Chitosan as a delivery vehicle for siRNA 
 
Chitosan nanoparticles for siRNA delivery has been widely studied and modified for pDNA 
delivery, less research is available for the implementation of siRNA delivery. Complexes 
between siRNA and chitosan are formed spontaneously as a result of electrostatic interactions 
between the negatively charged phosphate groups of siRNA and the chitosans positively 
charged groups (Reischl and Zimmer 2009).   
 
 
Figure 2.6 Preparation of chitosan/siRNA polyplexes based on electronegative interactions. 
Modified from (Mao et al. 2010). 
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Although most chitosans are able to compact nucleic acids into nanosized polyplexes, the 
stability and properties of polyplexes strongly depend on chitosan structural variables.  The 
siRNA delivery can be varied by the molecular weight (Mw) of the chitosans which affects 
polymer chain entanglement, further influencing its complexing ability with siRNA 
(Rudzinski and Aminabhavi 2010).  
 
The molecular weight of the chitosans are often given in statistical terms like number average 
and weight average (Mn and Mw), Polydispersity index (PDI) defined by Mn/Mw ratio or 
number average degree of polymerization (DPn), because of its polydisperse nature (Wang et 
al. 2010).  High Mw chitosan will entangle siRNA more readily than low Mw chitosan, which 
results in binding siRNA more efficiently and protecting the condensed siRNA from 
enzymatic degradation and serum components. (Rudzinski and Aminabhavi 2010).  
 
Furthermore, the molecular weight will influence the size of the chitosan/siRNA polyplexes, 
which is an important aspect in cellular uptake. Furtehermore, the fraction of acetylated units 
(FA) of chitosans determines the positive charge density and a lower FA results in increased 
positive charge that enables a greater siRNA binding capacity (Liu et al. 2007).  Moreover, 
the ratio of chitosan amino groups to RNA phosphate groups (N/P ratio) influences the ability 
of the particles to efficiently condense siRNA and interact with the negatively charged cell 
membranes (Mao et al. 2010). Together, all these properties together determine the overall 
charge and size of the chitosan/siRNA complex and ultimately the transfection efficiency 
(Rudzinski and Aminabhavi 2010). 
 
Another factor that may influence the transfection efficiency is the pH of the system, the 
interactions strengths between siRNA and chitosan are pH dependent and the adhesive 
interactions decreases with increasing  pH (Mao et al. 2010; S. Xu et al. 2007). Furthermore, 
the presence of serum may interfere with the transfection and chitosan/siRNA polyplexes 
have been shown to effectively protect siRNA from degradation of nucleases in 10% 
serum(Katas and Alpar 2006). Additionally, siRNA concentration, polyplex preparation 
techniques and route of administration are important aspects in formulation of efficient 
chitosan nanoparticles.  
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2.2.3 Chitosan/siRNA polyplex modifications 
 
Chitosan nanoparticles have been modified and substituted in many ways in the search for an 
optimal gene delivery particle. One of the major obstacles concerning siRNA delivery with 
chitosan nanoparticles for in vivo applications is the physical and colloidal stability. This can 
to some extent be overcome by the incorporation of DNA and PEGylated chitosans 
respectively. Further, there is a need for serum stability and targeting ligands may be 
necessary for the correct cellular localization of the nanoparticles.  
 
One method of preventing self-aggregation and undesired interactions with unwanted 
components in blood is to employ steric stabilization.  Polythethylene glycol (PEG) has been 
conjugated to different non-viral delivery carriers, and the resulting PEGylated particles have 
demonstrated increased salt and serum stability (Jiang et al. 2007). Another means of 
copolymerization is Polyethyleneimine (PEI), which also has been used as a modifier for 
chitosan vector derivation but can exhibit high toxicity to cells and is need for further 
optimization (Wong et al. 2005). 
 
Many of the nanoparticles developed cannot be used in clinical settings due to nonspecific 
delivery, which may lead to unwanted side effects. Preferably, the delivery system should 
show enhanced concentrations of therapeutic payloads at disease sites, minimize concerns 
about off-target effects, and ultimately raise the therapeutic index (Han et al. 2010; Whitehead 
et al. 2009). Therefore, the introduction of targeting ligands may increase the specificity and 
safety of the delivery agent. A novel tumor targeted delivery system for siRNA has recently 
been demonstrated by using an Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle for 
selective intratumoral delivery by binding to the ανβ3 integrin (Han et al. 2010) 
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2.3 P-glycoprotein 
 
In this thesis we chose a target with a high clinical relevance, more specifically the down 
regulation of the P-glycoprotein pump in rat brain endothelial cells by chitosan-siRNA 
transfection. In this section we give a background for the target and its localization. 
 
P-glycoprotein (P-gp) is a member of the ABC transporter family, expressed by the mdr1 
gene The P-gp is found to be concentrated in a small number of specific sites, certain cell 
types in liver, pancreas, kidney, colon, show specific localization of P-glycoprotein (Thiebaut 
et al. 1987). They suggested that the protein plays a role in the normal secretion of 
metabolites and certain anti-cancer drugs into bile, urine, and directly into the lumen of the 
gastrointestinal tract. Additionally P-gp is found on the apical side of brain endothelial cells, 
mediating active efflux of xenobiotics from the cells to the blood. Figure 2.7 shows a 
simplified version of the function of P-gp. 
 
 
 
Figure 2.7 Simplified P-glycoprotein structure and function in the cell membranes (Edwards 
2003). 
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More importantly, P-gp is often associated with multiple drug resistance (MDR) in cancer cell 
lines, by downregulating its expression we can dramatically improve the medical treatment. 
The role of P-glycoprotein inhibitors in drug delivery have been extensively studied and 
reviewed, a number of inhibitors have been developed but their toxicity and unfavorable 
pharmacokinetics have limited their clinical use (N. Akhtar et al. 2011; Sharom 2006) 
 
The implementation of siRNA technology to temporarily and specifically downregulate the 
expression of P-gp holds great potential for investigation both in vitro and in vivo. (Fuest et 
al. 2009; S. H. Lee and Sinko 2006). Lipid based reagents have been used to deliver naked 
siRNA targeting P-gp in vitro (Wu et al. 2003) and in vitro by simple IV injection  of 
modified siRNA (Su et al. 2005). Inhibition of P-gp expression by naked siRNA transfection, 
siRNA incorporated plasmid transfer, and stable siRNA transfection were compared and the 
most dramatic silencing of P-gp was obtained in stably transfected cell lines (D. Xu et al. 
2004). 
 
This makes the P-gp pump a highly relevant clinical target for chitosan/siRNA mediated 
downregulation. When this thesis was written, there was no published research on the use of 
chitosan based nanoparticles for siRNA downregulation of the P-gp pump. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
 
2.4 Blood brain barrier 
 
The blood brain barrier (BBB) is formed by the blood capillary endothelial cells in the brain 
which are closely linked together by tight junctions. Its main purpose is to protect the central 
nervous system (CNS) from the harmful effects of the many toxic substances that may 
adversely affect brain function. This effective protection ultimately results in the limited entry 
of 95% of drug candidates with potential benefits for CNS diseases (Fromm 2004; Fuest et al. 
2009). Diseases often accociated with the BBB and either upregulation or downregulation of 
P-gp expression include epilepsy, depression, brain tumors, brain HIV, Alzheimers and 
Parkinsons disease (Löscher and Potschka 2005). 
 
 
Figure 2.8 Schematic comparison of a brain capillary with a capillary in the periphery. (Löscher 
and Potschka 2005) 
 
Many approaches have been made for brain drug delivery, trans-cranial/trans-nasal, BBB 
disruption, lipidization of small molecules, transport of large-molecule drugs with molecular 
Trojan horses, all with variable obstacles and results (Pardridge 2007).  
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The rat brain endothelial cell line (RBE4) is a suitable in vitro model for studies on BBB 
permeability and transport functions as it expresses many of the BBB specific properties. 
(Roux and Couraud 2005). Furthermore, RBE4 cell monolayers have been used to investigate 
transport of large molecules, potentially useful drug delivery vectors such as 
immunoliposomes and nanoparticles (Alyaudtin et al. 2001; Cerletti et al. 2000) More 
importantly, the RBE4 cells stably expresses P-gp (though downregulated) in cell culture,  
making it well suited for downregulation studies of the transporter (Regina et al. 1998). 
 
Taken together, use of the RBE4 cell line as a model for BBB and investigation of chitosan 
mediated siRNA downregulation of the P-gp pump could provide us with the ability to 
increase the intracellular accumulation of drugs and thus improve treatment of the various 
diseases. 
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2.5 Fluorescence based techniques 
 
Throughout this thesis, a majority of the techniques used for analysis is based upon the 
principle of fluorescence.  Fluorescence can be defined as “the molecular absorption of light 
energy (photon) at one wavelength and its re-emission at another, usually longer, 
wavelength”. 
 
The fluorescence process can be broken down into three phases: 
1. Excitation - absorption of light of an appropriate wavelength by fluorophore. 
2. Excited state - fluorophore undergoes vibrational and conformational changes. 
3. Emission - photon of light is emitted. 
 
The fluorescence process is cyclical therefore a fluorophore can be excited repeatedly (GE-
Lifesciences). Specific biological and inorganic materials have the capacity to absorb light of 
a particular wavelength, this energy excites electrons of a low energy state to a higher state, 
loss of energy is emitted as fluorescent light which can be detected be photomultiplier tubes in 
the case of flow cytometric instruments (Warnes). A Jablonski energy diagram i presented in 
figure 2.9. 
 
 
Figure 2.9  Jablonski energy diagram of fluorescence (Warnes). 
 
In this thesis we use flow cytometry for estimation of knockdown and uptake in cells as well 
as confocal laser scanning microscopy for vizualisation of intracellular drug accumulation. 
These methods will be described briefly in the following sections. 
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2.5.1  Flow cytometry 
 
Flow cytometry is a technology that simultaneously measures and then analyzes multiple 
physical characteristics of single particles, usually cells, as they flow in a fluid stream through 
a beam of light. The properties measured include a particle’s relative size, relative granularity 
or internal complexity, and relative fluorescence intensity. These characteristics are 
determined using an optical-to-electronic coupling system that records how the cell or particle 
scatters incident laser light and emits fluorescence. A flow cytometer is made up of three 
main systems: fluidics, optics, and electronics (Rahman). 
 
• The fluidics system transports particles in a stream to the laser beam for interrogation. 
Essentially, the fluidics system consists of a central channel/core through which the sample is 
injected, enclosed by an outer sheath that contains faster flowing fluid. As the sheath fluid 
moves, it creates a massive drag effect on the narrowing central chamber. This alters the 
velocity of the central fluid whose flow front becomes parabolic with greatest velocity at its 
center and zero velocity at the wall. The effect creates a single file of particles and is called 
hydrodynamic focusing (USU) 
 
• The optics system consists of lasers to illuminate the particles in the sample stream and 
optical filters to direct the resulting light signals to the appropriate detectors. The cells in the 
sample are accelerated and individually pass through a laser beam for interrogation. Light 
scattering occurs when a particle deflects incident laser light.(Rahman) 
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Light that is scattered in the forward direction, typically up to 20° offset from the laser beam’s 
axis, is collected by a lens known as the forward scatter channel (FSC). The FSC intensity 
roughly equates to the particle’s size and can also be used to distinguish between cellular 
debris and living cells. Light measured approximately at a 90° angle to the excitation line is 
called side scatter. The side scatter channel (SSC) provides information about the granular 
content within a particle. Both FSC and SSC are unique for every particle, and a combination 
of the two may be used to differentiate different cell types in a heterogeneous sample. 
(Rahman) 
 
Figure 2.10  Light scattering properties of a cell (USU). 
 
• The electronics system converts the detected light signals into electronic signals that can be 
processed by the computer.  The detectors produce electronic signals (voltages) proportional 
to the optical signals striking them by photodetectors and then assigned a channel number on 
a data plot.(51) List mode data are collected on each particle or event. The characteristics or 
parameters of each event are based on its light scattering and fluorescent properties. The data 
are collected and stored in the computer. This data can be analyzed to provide information 
about subpopulations within the sample (BD-biosciences). 
 
An important principle of flow cytometry data analysis is to selectively visualize the cells of 
interest while eliminating results from unwanted particles e.g. dead cells and debris. This 
procedure is called gating. Cells have traditionally been gated according to physical 
characteristics. For instance, subcellular debris and clumps can be distinguished from single 
cells by size, estimated by forward scatter. Also, dead cells have lower forward scatter and 
higher side scatter than living cells 
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Single-parameter histograms are graphs that display a single measurement parameter (relative 
fluorescence or light scatter intensity) on the x-axis and the number of events (cell count) on 
the y-axis. The histogram is useful for evaluating the total number of cells in a sample that 
possess the physical properties selected for or which express the marker of interest. Cells with 
the desired characteristics are known as the positive dataset (Rahman). 
 
 
 
 
Figure 2.11 Example of a single parameter histogram (Rahman). 
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2.5.2  Confocal laser scanning microscopy  
 
A confocal microscope creates sharp images of a specimen that would otherwise appear 
blurred when viewed with a conventional microscope. This is achieved by excluding most of 
the light from the specimen that is not from the microscope’s focal plane. The image has 
less haze and better contrast than that of a conventional microscope and represents a thin 
cross-section of the specimen. The confocal microscope incorporates the ideas of point-by-
point illumination of the specimen and rejection of out-of-focus light(Semwogerere) 
 
The confocal principle in epi-fluorescence laser scanning microscope is diagrammatically 
presented in Figure 2. Coherent light emitted by the laser system (excitation source) passes 
through a pinhole aperture that is situated in a conjugate plane (confocal) with a scanning 
point on the specimen and a second pinhole aperture positioned in front of the detector (a 
photomultiplier tube). As the laser is reflected by a dichromatic mirror and scanned across the 
specimen in a defined focal plane, secondary fluorescence emitted from points on the 
specimen (in the same focal plane) pass back through the dichromatic mirror and are focused 
as a confocal point at detector pinhole aperture.  
 
The significant amount of fluorescence emission that occurs at points above and below the 
objective focal plane is not confocal with the pinhole (termed Out of- Focus Light Rays in 
Figure 2). Because only a small fraction of the out-of-focus fluorescence emission is delivered 
through the pinhole aperture, most of this extraneous light is not detected by the 
photomultiplier and does not contribute to the resulting image. (Claxton) 
 
The detected light originating from an illuminated volume element within the specimen 
represents one pixel in the resulting image. The computer can generate a three-dimensional 
picture of a specimen by assembling a stack of these two-dimensional images from successive 
focal planes. In addition, confocal microscopy provides a significant improvement in lateral 
resolution and the capacity for direct, non-invasive serial optical sectioning of intact, thick 
living specimens with an absolute minimum of sample preparation.  
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As laser scanning confocal microscopy depends on fluorescence, a sample usually needs to be 
treated with fluorescent dyes to make things visible. However, the actual dye concentration 
can be very low so that the disturbance of biological systems is kept to a minimum. Some 
instruments are capable of tracking single fluorescent molecules. Additionally transgenic 
techniques can create organisms which produce their own fluorescent chimeric molecules, 
such as a fusion of GFP, Green fluorescent protein with the protein of interest. (Quanta-tech). 
 
 
 
 
 
Figure 2.12 Schematic diagram of the optical pathway and principal components in a laser                      
scanning confocal microscope (Claxton). 
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3. Materials and methods 
3.1 Materials 
 
The human lung cancer cell line (H1299) was a gift from Jørgen kjems, inst. for molecular 
biology at the University of Århus, Denmark. The rat-brain endothelilial cell line (RBE4) was 
a gift from Tore Syvertsen, inst. for nevromedisin at St Olav hospital, Norway. 
 
The linear chitosans used in this thesis were developed by the department of biotechnology, 
Norwegian University of Science and Technology and supplied by the courtesy of post doc 
Sabina P. Strand. Producers and production numbers of all reagents used are given in 
appendix A, some physiochemical properties of the chitosan used are given in table 2.1. 
 
Table 3.1 Physical and chemical properties of the chitosans used in this study. DPn, Mn, Mw and 
PDI. 
Notation Mn 
(kDa) 
Mw 
(kDa) 
DPn PDI 
DPn 54 10.8 16.4 54 1.52 
DPn 200 39.8 74.5 199 1.87 
DPn 250 49.5 100.3 247 2.03 
DPn 300 64.1 141.6 320 2.21 
DPn 400 75.1 203 375 2.70 
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3.2 Cultivation and passaging of cell lines 
 
The H1299 cells were cultivated in RPMI medium (Sigma) supplemented with 1% non-
essential amino acids NEAA (Gibco), 100U/mL Penicillin/100µg/mL streptomycin; PEST 
(sigma) or 300µg/mL G418 (Sigma). The RBE4 cells were cultivated in αMEM (Gibco) 
supplemented with 1% NEAA, 10% heat inactivated fetal bovine serum; FBS (Gibco), PEST 
or 300µg/mL G418 and 100ng/mL growth factor bFGF. The same passaging procedure was 
performed for both cell lines (H1299 and RBE4):  
 
For cell passaging the cells should be ~95 % confluent. Old medium was removed from the 
flask and the cells were rinsed with 10-13 mL of warm phosphate buffered saline; PBS 
(Gibco) by swinging gently and removing it. 2-3 mL trypsin/EDTA (Sigma) was added on the 
roof for detachment of cells and poured out leaving ~1mL, incubated at 37°C and 5% CO2  for 
2-3 min. The flask was shaken carefully with hand palm for detachment and checked under 
the microscope. In order to inactivate the trypsin, 7 mL growth medium was added and mixed 
well by pipetting up and down 10-20 times. The cell suspension was transferred to a 50 mL 
tube (possibly adding more medium in order to reach a total volume of 10mL) and mixed well 
again for equal cell distribution.  
 
Further, a small volume was transferred to an eppendorf tube for cell counting in a bürker 
counting chamber and calcultation of medium required for re-suspending the cells in a 
suitable concentration (eg. 1x10
6
 cells/mL). The 50 mL tube was centrifuged for 5 min at 
1500 rpm, the medium removed and the pellet re-suspended in the calculated volume of 
medium. An appropriate amount of cells (typically 1x10
6
 cells/mL) was transferred to a new 
labeled flask with 14 mL medium and put on incubation at 37°C in a humidified atmosphere 
with 5% CO2. The cells were checked regularly (preferably every day) and the medium 
changed when necessary, the cells grew confluently after 3-4 days.  
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3.3 Seeding cells in 96/24- well plates 
 
Seeding was performed after cell passaging, using the remaining cell suspension with 1x10
6
 
cells/mL. The suspension was further diluted with medium containing PEST to appropriate 
concentration (typically 7500-45000 cells/mL). The cells were seeded in the 94/24 tissue 
culture well plates (collagen coated for RBE4 cells) by pipetting the desired volume (100/600 
µL) of the cell suspension in each well and incubated at 37°C and 5% CO2. The cells were 
ready for transfection 24-48 hrs after seeding.  
3.4 Polyplex formation and transfection  
 
Before any transfection experiment, the quality of the seeded cells was checked. The medium 
was poured out of the pre-seeded plates onto tissue paper and washed with 200 µL/well pre-
heated hank’s balanced salt solution; HBSS (Gibco). The plate was incubated at 37°C and 5% 
CO2 until the time of transfection (15-20 min). Formulation of polyplexes can be found in 
appendix B.  
 
The mixtures were prepared by first adding MQ water to the tubes followed by siRNA. 
Chitosan was added while stirring with a vortex mixer (~1200 rpm).    The complexes were 
incubated 30 min before the tonicity of the formulations was adjusted (1:1) with hypertonic 
OptiMEM pH 7-7.2 (OptiMEM (Gibco)+ 270mM Mannitol (AnalaR® + 20mM HEPES 
(Sigma)) for a osmolarity of 300 mOsm/kg and pH 7.2. 50 µL of transfection mixture was 
added to each well in the 96 well plate and incubated at 37°C and 5% CO2 for 4-5hrs. The 
transfection mixture was poured out and replaced with 200µL/well growth medium 
containing PEST. For uptake experiments, preparation and analysis was performed right after 
incubation with complexes while 24-120hrs for knockdown and cytotoxicity experiments 
 
Prosedure for other transfection reagents used:  
Turbofect
TM
  (Fermentas) transfects the same way as for chitosans with the exeption of using 
OptiMem instead of MQ water and hypertonic OptiMem when preparing the polyplexes,  
Lipofectamine
TM
 RNAiMAX (Invitrogen) polyplexes were prepared the same way as 
Turbofect, but siRNA-OptiMem and chitosan-Optimem were mixed in separate tubes and 
combined by pipetting. 
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3.5 GFP knockdown measured by flow cytometry 
 
The H1299 cells express enhanced green fluorescent protein (eGFP) with a halftime of 2hrs, 
the eGFP gene is incorporated into the cell line by transfection.  In order to investigate 
efficient transfection and knockdown in the cells, the GFP expression was analysed after 
transfection with GFP-siRNA by flow cytometry. ~7500 cells/well were seeded in 96 well 
plates (or 45000 for 24-well plates). The cells were transfected the next day as described 
previously and incubated for 5hrs before replacing the complexes with 200 µL medium and 
further incubated for 48hrs. In order to prepare the samples for flow analysis the cells were 
washed twice with 200µL PBS and 25µL trypsin/EDTA was added for detachment of cells. 
After incubation at 37°C and 5% CO2 for 2-3 min, 150µL ice-cold PBS with 5% FBS was 
added and the cells were re-suspended carefully. The samples was transferred from the wells 
into flow tubes by filtering through 40 μm nylon mesh (BD) filter caps and kept on ice before 
analysis.  
 
A Gallios flow cytometer  (Beckman Coulter) equipped with the 488nm laser line, a 525/40 
band pass filter and channel FL 1 for collection of emitted light.  A dot plot of forward scatter 
vs side scatter was used to determine a collection gate for the cells, leaving out dead cells, 
debris and cellular aggregations. The gate was set according to the positive cells (untreated) in 
order to exclude autofluorescence and 10 000 gated events was counted for each sample. 
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3.6 Alexa 647-siRNA uptake measured by flow cytometry 
 
In order to determine cellular uptake of the polyplexes, the cells were transfected with 
fluorescent siRNA and ananlysed by flow cytometry. ~10 000 cells/well was seeded in 96 
well plates (or 60000 cells/well in 24-well plates) and incubated for 24hrs. The cells were 
transfected as usual with Alexa647-labelled siRNA, after incubating for 4hrs the polyplexes 
were removed and washed with 200µL PBS. 200 µL medium containing PEST was added and 
the cells were incubated for 30 min. The medium was removed and replaced with 200 µL 
medium containing heparin (1mg/mL) to dissociate and remove the cell surface-associated 
complexes and incubated for another 30 min. The medium was removed and the cells washed 
twice with 200 µL PBS before adding 25mL trypsin for detachment of cells. After incubating 
2-3 min the cells were re-suspended in 150µL ice-cold PBS with 5% FBS.  
 
The suspension was transferred from the wells into flow tubes by filtering through 40 μm 
nylon mesh (BD) filter-caps (combining two wells for 96-well plates, one for 24-well plates). 
The samples were put on ice before running flow measurements using the 488nm laserline 
and a 660/20 band pass filter, emitted light was collected at channel FL6. The gate was set 
according to samples of untreated cells as negative controls to set a threshold for fluorescence 
above the levels of autofluorescence and the cell count set to 10 000 gated events per sample.  
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3.7 GAPDH knockdown assay 
 
KDalert
TM
 GAPDH assay kit (Applied Biosystems) was used to facilitate identification of 
optimal siRNA delivery conditions by assessment of GAPD expression and knockdown. The 
assay measures the conversion of NAD+ to NADH by GAPDH in the precence of phosphate 
and G-3-P (Glyceraldehyde-3-phosphate), the rate of NADH production is proportional to the 
amount of GAPDH enzyme present. 
 
Approximately 5000 cells/well were seeded in 96-well plates and transfected as previously 
described. Medium was removed from the well plates 48hrs after transfection and 100-150µL 
lysisbuffer was added to each well. The plate was sealed with parafilm and put in the 
refrigerator for 20 min. During the lysis reaction, a mastermix was prepared by using 
calculated amounts of solutions A, B and C needed for each well (Sol. A : 88,8 µL + 5%, Sol. 
B: 0,68 µL + 5% Sol C: 0,47 µL + 5%).  
 
The solutions were mixed by stirring on a vortex mixer. The well plate was taken out of the 
refrigerator and the cell lysate was pipetted up and down five times. 10 µL of the lysate was 
transferred to ½ area well plates, 10 µL MQ water was added to three wells not containing 
cells for blank measurements. 90 µL mastermix was added to each well and absorbance was 
measured at 615 nm after 5, 10, 15, 20, 25, and 30 minutes on a UV/VIS plate reader 
(SpectreMax Plus
384
, Molecular Devices). The blank measurement values were subtracted 
from the sample values and presented as percent GAPDH of untreated cells. 
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3.8 Cytotoxicity assays 
3.8.1 AlamarBlue assay for estimation of metabolic acivity 
 
AlamarBlue® is a cell health indicator used to establish metabolic activity and relative 
cytotoxicity of agents by flurometric/colometric measurements. The assay incorporates an 
oxidation-reduction indicator that both fluoresces and changes color in response to chemical 
reduction of growth medium resulting from cell growth. The compound resazurin is reduced 
to the highly fluorescent resafurin and the absorbance is monitored at 570nm and 600nm (Al-
Nasiry et al. 2007). 
 
The cells were seeded in 96 well plates with RPMI (H1299 cells) or MEMα (RBE4 cells) 
medium. The next day cells were transfected as usual and incubated at 37°C and 5% CO2 for 
4hrs. 1% Triton X 100 lyses the cells and was added to untreated cells; it shows if the assay 
works and was used as a positive control. The polyplexes/medium/triton was removed after 
4hrs and 200µL medium was added, 24hrs after transfection the medium was changed. 48hrs 
after transfection the cells were washed two times with PBS and 10 µL alamarBlue reagent 
mixed with 100 µL DMEM (without phenol red) for each well was added  (including wells 
without cells for blank measurements), incubated at 37°C and 5% CO2 for 4hrs. After 
incubation the plate was analyzed on a UV/VIS plate reader at absorbances 570 and 600 nm.  
 
3.8.2 Propidium iodide staining for cell viability 
 
Propidium iodide is membrane impermeant and thereby excluded by viable cells but can 
penetrate the cell membranes of dying or dead cells (Nocker et al. 2006). It is a fluorescent 
compound and by monitoring the fluorescence intensity by flow cytometry it is possible to 
distinguish viable from dead cells. 
 
In order to stain and evaluate cell viability the transfected samples were treated with 1 µg/mL 
propidium iodide (PI) prior to flow analysis. The samples were analysed using a 488 laser line 
and emitted light collected through channel FL3. The gate was set according to samples of 
untreated cells as negative controls to set a threshold for fluorescence above the levels of 
autofluorescence from viable cells. The cell count was set to 10 000 gated events per sample 
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3.8.3 Bicinchoninic acid (BCA) assay for total protein determination 
 
The BCA protein assay kit 
TM
 from Pierce combines the reduction of Cu
2+
 to Cu
1+
 by protein 
in an alkaline medium with the highly sensitive and selective colorimetric detection of the 
cuprous cation (Cu
1+
) by bicinchoninic acid. The BCA/copper complex exhibits a strong 
linear absorbance with increasing protein concentrations (Krohn 2001). 
 
The medium was removed from the wells and the cells were washed with 200 uL PBS before 
addition of 100 µL ice-cold Reporter lysis buffer (Promega). Samples for the standard curve 
was prepared by diluting bovine serum albumin (BSA) stock solution (2mg/mL) in lysis 
buffer in the range 0 - 2000 µg/mL.  The plates were thawed at 37°C and 5% CO and the 
bottom of the wells were scraped for 5-10 seconds in order to obtain a homogenous cell 
lysate. 10 µL of the cell lysates and standards were transferred to a ½ area 96-well plate, 
blank samples contained only lysis buffer. Amount of BCA working reagent A and B were 
calculated for lysates, standards and blank, mixed (50:1) and 100 µL of the solution were 
added to each well.  
 
The plate was wrapped in aluminum foil and incubated at at 37°C and 5% CO for 30 min. 
Absorbance was measured at 570 nm using a UV/VIS plate reader. The blank measurements 
were subtracted from the sample values and protein concentration was calculated from the 
standard curve, presented as ug/mL cell lysate. 
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3.9 Rhodamine 123 efflux assay 
 
Rhodamine is a fluorescent dye and a substrate for the P-gp pump, intracellular accumulation 
of Rhodamine can be used as a measurement of the pumps efflux activity and thus 
knockdown efficiency. Verapamil is a well known inhibitor of the P-gp pump and was used as 
positive control.  
 
Approximately 10 000 cells were seeded in 96-well plates and the assay was performed 48hrs 
after chitosan/siRNA transfection of RBE4 cells. The cells were washed with warm PBS, 50 
µL of 10 µM Verapamil solution in Optimem was added to the cells that should be inhibited 
with Verapamil. 50 µl Optimem was added to the rest of the cells followed by incubation at 
37°C and 5% CO2 for 45 min. After incubation, 50 µL of 10 µM Rho123 solution in Optimem 
was added (not removing Optimem with/without Verapamil). The plate was wrapped in Al-
foil and incubated for 15 min. After incubation, the solutions were removed and the cells 
washed with warm PBS. 200 µl of growth medium was added placed on incubation for 2hrs at 
37°C and 5% CO2.  
 
The cells inhibited with Verapamil were incubated in growth medium containing 5 µM 
Verapamil. After incubation the cells were washed rapidly with 200 µL cold PBS, detached 
with 25µL trypsin and re-suspended in 150uL ice-cold PBS with 4% FBS. The samples were 
filtered into flow tubes though filter caps while being kept on ice. It was important to keep the 
cells on ice while preparing the samples and not running all the samples at the same time on 
the flow cytometer in order to avoid leakage of Rho12. The samples were run using the argon 
488nm laserline and the emission was collected at the FL1 channel. The gate was set 
according to samples of untreated cells as negative controls to set a threshold for fluorescence 
above the levels of autofluorescence and the cell count set to 10 000 gated events per sample 
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3.10 Confocal laser scanning microscopy of RBE4 cells   
 
The anticancer drug Doxorubicin is a substrate for the P-gp pump and allows for visualization 
of intracellular accumulation in the treated cells. The cells were seeded in collagen coated 
eight-chamber microscopic slides (Ibidi GmbH), 18750 cells/chamber. The cells were 
transfected as usual with 125 µL polyplexes/well and incubated for 5 hrs before the medium 
was changed, and again after 24hrs. Cells for positive control were treated with 5µM 
Verapamil in αMEM for 30 min before the cells were treated with αMEM supplemented with 
50µM Doxorubicin (stock solution 3443µM) and incubated for 2hrs.  
 
Medium was removed and 150 ul CellMask plasma membrane stain 5µg/mL (Invitrogen) was 
added and incubated for 5 min in 37°. CellMask was removed and the cells washed with 
300uL PBS three times and 300 uL medium was added right before microscopy.  
Doxo-accumulation was studied and merged with cellmask to show confluence.  A LSM 510 
(Carl Zeiss Jena GmbH, Germany) confocal microscope with a c-Apochromat 40x/1.2 NA W 
corr objective was used to investigate the cells.   
 
Doxorubicin was excited using the 488-nm argon laser line and CellMask using the 633-nm 
HeNe laser line. The emitted light was collected using 500-550 nm band pass and 651-704 nm 
long pass filters. Resolutions of 512 x 512 pixels was used for all of the images, image 
acquisition and processing were conducted using the LSM Image Browser (Zeiss) software 
program. 
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4. Results 
This section begins with a general screening of chitosan/siRNA polyplexes transfection in the 
human lung cancer cell line (H1299) as a model-cell line in the anticipation of rat brain 
endothelial cells (RBE4). Uptake and knockdown efficiency was investigated followed by 
cytotoxicity screening of the chitosan/siRNA polyplexes. The following sections will focus on 
the RBE4 cells where general uptake and knockdown was investigated as well as cytotoxicity. 
Further, knockdown of the mdr1a/b mRNA coding for the P-glycoprotein pump was 
determined by drug efflux /retention studies and confocal laser scanning microscopy. 
 
Commonly used abbreviations in the graphical presentation of the results throughout this 
section includes; C for chitosan followed by DPn, T for targeting, NT for non-targeting, N for 
naked, Turbo for Turbofect and R-Max for RNAiMAX. All raw and supplemental data for the 
results can be found in the indicated appendices. 
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4.1 DPn and N/P ratio screening in  H1299 cells 
 
The human lung cancer cell line H1299 and was used in order to establish and select the 
optimal DPn and N/P ratio for further studies. Transfection and assay procedures were 
performed with these cells for training and anticipation of rat brain endothelial cells RBE4. 
4.1.1 Uptake of chitosan/siRNA polyplexes in H1299 cells 
 
The first barrier nanoparticles encounter is the cell wall and its subsequent entry into cells by 
endosomal encapsulation. In this experiment different chitosan/siRNA polyplexes were 
compared in terms of their ability to deliver siRNA by using fluorescently labeled Alexa 647 
siRNA.  
 
The chitosans chosen for formulation with GFP-siRNA were all linear with DPn 54, 200, and 
300 with FA = 0. The siRNA concentration was 45nM and the N/P ratios were 10 and 30 for 
each sample. The commercial transfection reagent Turbofect was included for comparison 
and naked siRNA served as negative control as it was not expected to enter the cells.  
 
The cells were transfected as described previously and the cellular uptake of the chitosan/ 
siRNA complexes in H1299 cells was investigated 4hrs after transfection by flow cytometry. 
The results are presented in figures 4.1 and 4.2, supplemental data for the presented figures 
can be found in appendix C. 
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Figure 4.1 The relative amount of internalized siRNA in H1299 cells treated with chitosans DPn 
54, 200, 300 complexed with Alexa647-siRNA in N/P ratios of 10 and 30. The results are 
presented as percent median FI of control. Each data point is the mean value ± standard 
deviation (n=3). 
 
 
Figure 4.2 Fluorescence intensity overlay-plots for cells treated with chitosan DPn 300 complexed 
with Alexa647-siRNA in N/P ratios of 10 and 30 compared to untreated control cells. Results are 
presented as fluorescence intensity plotted against cell count (number of events) followed by its 
median value.  Cell count was set to 10000 and measured through channel FL6. 
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The chitosan-siRNA complexes all showed increasing uptake efficiency with higher DPn and 
N/P ratio, naked siRNA did not mediate uptake on its own. This is similar to the observed 
knockdown efficiency in cells treated with DPn 300. Samples with N/P ratios of 30 had the 
highest uptake closely followed by N/P 10, the longer chitosans worked better with lower N/P 
ratios compared to chitosan with a low DPn. Both the untreated cells and the cells treated with 
naked siRNA resulted in a median fluorescence close to zero, thus confirming uptake 
specificity. 
4.1.2 GFP knockdown in H1299 cells 
 
H1299 cells express green fluorescent protein (GFP) which can be efficiently downregulated 
by the introduction of siRNA. This stable reporter gene should thus give a representative 
picture of transfection efficiency by measurement of the median fluorescent intensity. 
 
The chitosans chosen for formulation with GFP-siRNA were all linear with DPn 54, 200, and 
300 with FA = 0. The antiGFP-siRNA concentration 45nM and the N/P ratios were 10 and 30 
for each sample. Additionally, chitosan polyplexes with non-targeting siRNA were used in 
order to distinguish sequence-specific silencing from non-specific effects. Commercially 
available Turbofect
TM
 transfection reagent was included for comparison of transfection 
success and knockdown efficiency. Untreated cells served as negative control, the gate was 
set according to these in order to define GFP positive cells. 
 
The cells were transfected as previously described and the median fluorescence intensity (FI) 
was measured by flow cytometry 48hr after transfection. The results are presented in figure 
4.3 and 4.4, supplemental data for the presented figures can be found in appendix C. 
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Figure 4.3 GFP expression in H1299 cells measured by flow cytometry. The cells were 
transfected with chitosan DPn 54/200/300 complexed with antiGFP-siRNA in N/P ratios of 10 
and 30, non-targeting controls and turbofect. Untreated cells were set as baseline control and the 
results are presented as percent median FI of control. Each data point is the mean value ± 
standard deviation (n=3). 
 
 
 
Figure 4.4 Fluorescence intensity overlay-plots for cells treated with chitosan DPn 200 complexed 
with antiGFP-siRNA in N/P ratios of 10 and 30 compared to untreated control cells. Results are 
presented as fluorescence intensity plotted against cell count (number of events) followed by its 
median value. The cell count was set to 10000 events and measured through channel FL1. 
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It can be observed from figure 4.3 that the chitosans with high DPn and N/P ratios displayed 
the best knockdown efficiency with a median FI ~15% of untreated cells. N/P ratios of 30 
seemed to be twice as efficient as the ones with N/P 10, exept for DPn 54 where a N/P ratio of 
10 had little effect compared to N/P 30.  The commercial Turbofect transfection reagent had 
no apparent effect on knockdown, it rather showed an increase in median fluorescence, even 
with non-targeting siRNA.  
 
We also wanted to investigate the effect of serum addition at transfection.  The mere intention 
was to see if the complexes could successfully form and in what way may affect the 
transfection efficiency. Therefore 10% FBS was added to OptiMem at transfection using the 
same sample formulations and analysed after 48hrs by flow cytometry. The results are 
presented in figure 4.5 and 4.6, supplemental data for the presented figures can be found in 
appendix C. 
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Figure 4.5 GFP expression in H1299 cells measured by flow cytometry. The cells were 
transfected in the precence of 10% serum with chitosans DPn 54/200/300 complexed with 
antiGFP-siRNA in N/P ratios of 10 and 30. Untreated cells were set as baseline control and the 
results are presented as percent median FI of control. Each data point is the mean value ± 
standard deviation (n=3). 
 
 
Figure 4.6 Fluorescence intensity overlay-plots for cells transfected in 10% serum with chitosan 
DPn 300 complexed with GFP-siRNA in N/P ratios of 10 and 30 compared to untreated control 
cells. Results are presented as fluorescence intensity plotted against cell count (number of 
events) followed by its median value. Cell count was set to 10000 and measured through channel 
FL1. 
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Presence of serum at transfection seemed to negatively affect the knockdown efficiency of all 
chitosans with N/P 10, it never reached below the threshold value of the control cells 
(untreated). The same is observed for LIN54 with N/P 30 which were expected to exhibit a 
low yet distinguishable knockdown. Longer chitosans (200/300) with N/P 30 showed a 
similar reduction of GFP expression as the previous experiment without transfection with 
serum.  
 
Cells treated with Turbofect displayed a reduction in GFP expression, also the samples with 
non-targeting siRNA. This may be related to toxicity as in some of the preliminary 
experiments (not included) were it killed most of the transfected cells. It must however be 
taken into consideration that this is two individual GFP experiments and they are therefore 
subject to variability in sample preparation and analysis.  
4.1.3 GAPDH knockdown in H1299 cells 
 
GFP is artificially introduced whereas GAPDH is endogenously expressed in most 
mammalian cell lines. The RBE4 cells intended for use in the further studies do not express 
GFP, therefore GAPDH was chosen for analysis. The method was first performed with H1299 
cells in order to confirm transfection with chitosan/siRNA polyplexes.  
 
The polyplex formulations chosen for this experiment were the same as for the previous 
studies. The knockdown was determined by measuring the reduction in GAPDH enzyme 
activity in cells transfected with GAPDH siRNA relative to untreated cells which served as a 
negative control.  
 
The cells were transfected as described previously and analysed by absorbance measurements 
on a UV/VIS plate reader after 48hrs. The results are presented in figure 4.7, supplemental 
data for the presented figure can found in appendix C. 
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Figure 4.7 Enzymatic activity of GAPDH in H1299 cells treated with chitosans DPn 54/200/300 
complexed with GAPDH-or nontargeting siRNA in N/P ratios of 10 and 30 and turbufect. 
Untreated cells were set as baseline control and the results are presented as percent of control. 
Each data point is the mean value ± standard deviation (n=3). 
 
From the results in figure 4.7, chitosans with a higher degree of polymerization showed a 
more efficient knockdown of GAPDH activity. There were only subtle differences between 
DPn 200 and DPn 300 chitosans with a reduction of ~40% of control. DPn 54 with N/P 10 had 
a reduction similar to the non-targeting sample, suggesting little or no effect on knockdown. 
There was little observed difference between the chitosans with N/P ratios of 10 and 30, 
which corresponds with the previous GFP expression studies. The knockdown efficiency 
therefore seems to depend in a higher degree on the DPn rather than the N/P ratio of the 
chitosans.  The reduction of GAPDH activity in samples treated with non-targeting siRNA 
indicates that the chitosan may have a negative effect on the cells and suggests the need for 
further studies on cytotoxicity of the chitosans. 
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4.2 Cytotoxicity of chitosan and chitosan-siRNA polyplexes.  
 
When developing nucleic acid delivery systems, it is important that the components are 
biocompatible and display a low cytotoxicity. Here we take advantage of the body’s own 
machinery via RNAi and the fact that chitosans break down to charbohydrates and 
components that can be extruded from the body. Therefore it is expected that the chitosan 
nanoparticles will exhibit a tolerable toxicological profile in the H1299 cell line.  
 
It was desirable to investigate the possible long term cytotoxicity of the chitosan-siRNA 
polyplexes and naked chitosans on the H1299 cells. Over a five-day period the transfected 
cells were subjected to analysis by four different cytotoxicity assays: 
 
- Alamar blue assay for determination of metabolic activity. 
- PI staining for membrane permeability and thus cell viability.  
- Cell count for estimation of cell proliferation. 
- BSA assay for determination of total protein concentration.  
Only chitosan with DPn 200 and N/P 10 and 60 was chosen for investigation, due to the 
higher possibility of observed cytotoxicity with longer chitosans. Samples with naked 
chitosan and naked siRNA were included for determination of possible cytotoxic effects 
alone. Commercial RNAiMAX was used for comparison of its cytotoxicity relative to the 
chitosan and chitosan/siRNA polyplexes. The cells were transfected as normal and subjected 
to analysis after 24, 48 ,72, 96 and 120hrs.  
 
4.2.1 AlamarBlue assay 
 
Estimation of metabolic activity in the different samples were analysed by the alamarBlue 
assay. The cells were transfected with the complexes described above and analysed 24, 48, 
72, 96 and 120hrs after transfection with a UV/VIS plate reader at 570 and 600 nm. The 
results are presented in figure 4.8, supplementary data for the figure can be found in appendix 
D. 
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Figure 4.8 Metabolic activity of H1299 cells over 120hrs measured by alamarBlue assay. Cells 
were treated with chitosan DPn 200 complexed with non-targeting siRNA in N/P ratios of 10 and 
60, naked chitosan and siRNA, RNAiMAX. Untreated cells were set as baseline control and the 
results are presented as percent reduction of control. Each data point is the mean value ± 
standard deviation (n=4). 
 
The results in figure 4.8 show that chitosan DPn 200 polyplexes with N/P 10 and 60 both 
exhibited negligible reduction in metabolic activity of the cells. The amount of reduction in 
relation to untreated control had a maximum ~10% for all samples containing chitosan/siRNA 
polyplexes, the same is observed for the naked chitosan sample. The cells treated with naked 
siRNA displays comparable values to the untreated control cells. The commercial RNAiMAX 
transfection reagent displayed the most prominent reduction in metabolic activity, reaching 
~20% reduction and therefore displays a higher toxicological profile in this experiment. 
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4.2.2    Propidium iodide staining  
 
In order to stain and determine the amount of dead cells in the samples/evaluate cell viability 
the cell samples were treated with propidium iodide (PI) prior to flow analysis. PI is 
membrane impermeant and generally excluded by viable cells but can penetrate cell 
membranes of dying or dead cells. The samples were transfected as initially described and 
treated with PI directly prior to flow analysis after 24, 48, 72, 96 and 120hrs. The results are 
presented in figure 4.9, supplemental data for the figure can be found in appendix D. 
 
 
 
 
Figure 4.9 Cell viability in H1299 cells assayed by PI staining followed by flow cytometry over 
120hr. Cells were treated with chitosan DPn 200 complexed with non-targeting siRNA in N/P 
ratios of 10 and 60, naked chitosan and siRNA, RNAiMAX. Untreated cells were set as baseline 
control and the results are presented as median fluorescent intensity. Each data point is the 
mean value ± standard deviation (n=3). 
 
The observed results in figure 4.9 show an increase in PI permeability during the three first 
days followed by a reduction the last two days. There is no difference between chitosan 
polyplexes with N/P 10 and 60 as well as naked chitosan. Interestingly the chitosan treated 
samples displays similar permeability as naked siRNA. Untreated cells show a stable viability 
during exposure to PI throughout the 5-day period. RNAiMAX samples displayed a greater 
increase in PI permeability during the three first days. 
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4.2.3 Cell counting  
 
The same samples were assessed for proliferation by cell counting in bürker chambers over a 
five day period after transfection. It was expected that cells treated with complexes and naked 
chitosan would have the greatest growth retention and thereby have fewer cells pr mL than the 
samples with naked siRNA and the untreated cells. The results are presented in figure 4.10, 
supplemental data for the figure can be found in appendix D. 
 
 
Figure 4.10 Proliferation in H1299 cells by cell counting over 120hrs. Cells were treated with 
chitosan DPn 200 complexed with non-targeting siRNA in N/P ratios of 10 and 60, naked 
chitosan and siRNA, RNAiMAX. Untreated cells were set as baseline control and the results are 
expressed as cells/mL. Each data point is the mean value ± standard deviation (n=3). 
 
 
The results in figure 4.10 reflect a steady cell proliferation which reaches a plateau after four 
days. The samples treated with chitosan N/P 10 shows little reduction in growth compared to 
the untreated cells, the same is observed for naked siRNA. However, both the naked chitosan 
and the chitosan- siRNA complexes have an inhibitory effect when the N/P ratio is increased 
to 60. Treatment with RNAiMAX gave the most pronounced growth retention which also 
correlates to results obtained in the previous cytotoxicity experiments. 
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4.2.4 Bicinchoninic acid (BCA) assay  
 
BCA assay was used for total protein determination in the samples. The cells were transfected 
as previously described and analysed at 570nm on a UV/VIS plate reader  24, 48, 72, 96 and 
120hrs after transfection. The result is presented in figure 4.11, Supplemental data for the 
figure can be found in appendix D.  
 
 
Figure 4.11 Total protein concentration in H1299 cells determined by BSA assay over 120hrs. 
The cells were treated with chitosan DPn 200 complexed with non-targeting siRNA in N/P ratios 
of 10 and 60, naked chitosan and siRNA, RNAiMAX. Untreated cells were set as baseline control 
and the results presented as change in protein concentration (µg/mL cell lysate). Each data point 
is the mean value ± standard deviation (n=4). 
 
There is a linear increase in protein concentration which stagnates during the last 24hrs, these 
results correlates well with the cell count study. The samples are not easy to distinguish from 
another but there are notable differences between the extremities. RNAiMAX results in a 
continuous though negligible lower protein concentration than the other samples.  Untreated 
control and naked siRNA shows a slightly higher concentration.   
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4.3 Investigation of general uptake and knockdown in RBE4 cells  
 
The preceding work on H1299 cells was done in order to establish efficient chitosan/siRNA 
polyplex formulation for use in the RB4 cell line. For demonstration of efficient uptake and 
knockdown feasibility of the chitosan nanoparticles in the RBE4 cells, knockdown of 
GAPDH and uptake of fluorescently labeled Alexa 647 siRNA was investigated. 
4.3.1 Analysis of uptake in RBE4 cells by flow cytometry  
 
By using fluorescently labeled Alexa 647 siRNA complexed with chitosans, the uptake 
efficiency of the nanoparticles into RBE4 cells was investigated by flow cytometry. 
Based on the preliminary experiments with H1299 cells, chitosans with high Dpn and both a 
high and low N/P ratio was chosen for investigation of uptake in RBE4 cells. The chitosans 
used in this experiment was DPn 250, 300, 400 and 810, complexed with Alexa 647 siRNA all 
with N/P ratios of 10 and 60. The samples were analysed 4h after transfection by flow 
cytometry. The results are presented in figure 4.12, supplemental data for the figure can be 
found in appendix C. 
 
 
 
 
Figure 4.12 Relative amount of internalized siRNA in H1299 cells measured by flow cytometry. 
The cells were treated with chitosans DPn 250,300,400,810 complexed with Alexa647-siRNA in 
N/P ratios of 10 and 30. The results are expressed as median of fluorescence intensity (FI). Cells 
treated with siRNA were set as baseline control and the results are presented as median FI of 
control. Each data point is the mean value ± standard deviation (n=3). 
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The results presented in figure 4.12 shows an increasing uptake efficiency of chitosan/siRNA 
polyplexes with increasing DPn of the chitosans. This result corresponds with the previous 
result with H1299 cells. The difference in uptake efficiency is much more evident between the 
chitosans with N/P ratios of 10 than the ones with a N/P ratio of 60. The chitosan with DPn 
810 did not display the same level of internalization of polyplexes as the others, with a 
negligible effect at N/P 10. 
4.3.2 GAPDH knockdown in RBE4 cells 
 
The RBE4 cell line does not have the exogenous GFP gene, but do express GAPDH. The 
assay has been previously tested on H1299 cells (fig 4.7). The cells were transfected as 
described previously and analysed by flow cytometry after 48hrs. The results are presented in 
figure 4.13, supplemental data for the figure can be found in appendix C. 
 
 
Figure 4.13 Enzymatic activity of GAPDH in RBE4 cells treated with chitosans DPn 200,300,810 
complexed with GAPDH-siRNA in N/P ratios of  10 and 30, non-targeting samples and 
RNAiMAX. Untreated cells were set as baseline control and the results are presented as percent 
of control. Each data point is the mean value ± standard deviation (n=3). 
 
The results presented in figure 4.13 show that chitosan polyplexes with DPn 200 and 300 has 
the same effect on knockdown at N/P 60, with a ~50 % decrease of untreated control. This is 
comparable to the commercial RNAiMAX which show only a slightly higher effect on 
knockdown. The chitosan with DPn 200 and 300 with N/P 10 did not give a sufficient 
knockdown, only a mere ~10% of control.  
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4.3.3 Investigation of metabolic activity in RBE4 cells 
 
The alamarBlue assay was chosen in order to check for possible cytotoxicity of the chitosan 
nanoparticles on the RBE4 cells. The assay has been previously tested on the H1299 cells 
where a maximum reduction of ~15% in metabolic growth was found in the chitosans with 
DPn 200 and N/P 60 after 48 hrs. 
 
Chitosans with DPn 200 and 300 with N/P 10 and 60 was chosen for this experiment with an 
additional naked chitosan sample for both chitosans. The siRNA used was non-targeting as 
for the same experiment with H1299 cells (fig 4.8). Samples containing only siRNA were 
again used to show that does not mediate transfection on its own. RNAiMAX was included on 
the basis of comparison with a commercial reagent which in previous experiments has been 
seen to exhibit a higher toxicity profile. Triton lyses the cells and gives a direct indication that 
the assay works. 
 
The cells were analysed 48hrs after transfection with a UV/VIS plate reader at 570 and 600 
nm. The results are presented in figure 4.14, supplemental data for the figure can be found in 
appendix D. 
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Figure 4.14 Metabolic activity of RBE4 cells measured by alamarBlue assay. Cells were treated 
with chitosans  DPn 200, 300 complexed with non-targeting siRNA in N/P ratios of 10 and 60, 
non-targeting siRNA and naked siRNA, RNAiMAX. Untreated cells were set as baseline control 
and the results are presented as percent reduction of control. Each data point is the mean value 
± standard deviation (n=4). 
 
The results in figure 4.14 show that both chitosan nanoparticles with DPn 200/300 had a 
reduction of ~10-20% in metabolic activity at N/P 60. The samples with N/P 10 showed a 
reduction of ~5-10% while the naked chitosan exhibited a somewhat lower toxicity at N/P 60 
than the same samples complexed with siRNA. The triton treated samples showed a reduction 
of ~95 % of untreated control, indicating that the samples were lysed and that the assay 
worked.  
 
The commercial reagent RNAiMAX was again more toxic to the cells than chitosan with a 
mere ~35% reduction in metabolic activity. Samples treated only with naked siRNA gave no 
observed difference from the untreated control cells.  
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4.4 Rhodamine efflux in RBE4 cells after targeting the mdr1 gene 
 
Rho 123 was used as a functional assay for determination of P-gp knockdown. Rhodamine is 
a substrate and functional reporter for the P-gp pump and intracellular accumulation of 
Rhodamine should reflect low efflux and thus efficient knockdown of the P-gp gene. In these 
experiments the Rho123 assay was used in order to investigate efficient knockdown of the 
mdr1 gene expression compared to the commercially available Verapamil, which is a known 
inhibitor of the P-gp pump. 
 
4.4.1 Knockdown of P-gp in RBE4 cells 
 
Intracellular Rho 123 accumulation in cells can be used as assay for determining knockdown 
of the P-gp pump. The chitosans chosen for use in this assay were DPn 300 and DPn 400 all 
complexed with mdr1a/b in N/P ratios of 10. The calcium-channel blocker Verapamil is a 
specific inhibitor of P-gp modulated efflux and was used as positive control. 
 
The cells were transfected as usual and after 48hrs subjected to rho123 influx and Verapamil 
inhibiton prior to flow analysis. The results are presented in figure 4.15 and 4.16, 
supplemental data for the figures can be found in appendix E. 
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Figure 4.15 Rhodamine 123 efflux in RBE4 cells measured by flow cytometry. A) Cells were 
treated with chitosans DPn 300/400 and complexed with mdr1a/b-siRNA in a N/P ratio of 10. B) 
comparison of untreated cells and cells treated with 10µM Verapamil. The results are presented 
as percent reduction of control. Each data point is the mean value ± standard deviation (n=3). 
 
 
 
Figure 4.16 Overlay flow cytometry plots of fluorescence intensity in cells treated with chitosan 
Dpn 300 complexed with mdr1a-siRNA in an N/P ratio of 10, Verapamil treated cells and 
untreated control cells.  Results are presented as fluorescent intensity plotted against cell count 
(numer of events). Cell count was set to 10000 events and measured through channel FL6. 
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There is an increased intracellular accumulation of Rhodamine after treatment with mdr1a 
siRNA polyplexes while mdrb1 only had a minor effect compared to untreated control. Non-
targeting control and naked siRNA cells displayed negligible effects on Rho123 retenton in 
the cells and are comparable to the untreated control cells.  
 
These results reflect a 2/3 fold chitosan-mdr1a siRNA downregulation of the P-pg pump. 
However, the Verapamil treated cells displayed a much higher inhibition of the pump. 
Verapamil treated cell resulted in a median fluorescent value so high that is would be difficult 
to display the effects of chitosan/siRNA polyplexes. 
 
4.4.2 Rho123 accumulation with increasing Verapamil concentration 
 
It was desirable to investigate the effect on knockdown of Pgp with different Verapamil 
concentrations as well as rate of efflux of Rhodamine. Based on the preliminary experiments 
there was a difference in Rhodamine accumulation/efflux at 5uM and 10 uM Verapamil. 
Therefore cells were treated with 5, 10, 25, 50 and 250 uM Verapamil to see if there was any 
plateau where the cells stop taking up more Rhodamine. The results are presented in figure 
4.17 and 4.18, supplemental data for the figures can be found in appendix E. 
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Figure 4.17 Effect of Verapamil concentration on Rhodamine 123 efflux in RBE4 cells measured 
by flow cytometry. Cells were treated with 0, 10, 25, 50 and 250µM Verapamil prior to and 
during Rho123 influx. Results are presented as median fluorescent intensity of untreated control 
cells (0µM). Each data point is the mean value ± standard deviation (n=3). 
 
 
Figure 4.18 Overlay-plots of Rho123 fluorescence intensity in cells treated with 0, 5, 10, 25, 50 
and 250uM Verapamil. Results are presented as fluorescence intensity plotted against cell count 
(number of events). The cell count was set to 10000 events and measured through channel FL1. 
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It can be observed from figure 4.16 and 4.17 that the Verapamil effect on Rho123 efflux in 
the cells is concentration dependent. The intracellular Rhodamine increases continuously with 
higher concentrations and does not reach a plateau where the cells are saturated with the drug. 
  
4.4.3 Verapamil concentration-time effect on Rho123 efflux 
 
It was evident that there is an increase in intracellular Rhodamine with increasing Verapamil 
concentrations, an important factor for further use of the assay and comparison with published 
results.  
 
In order to investigate the rate of Rhodamine efflux, the incubation time (2hrs) with 
medium/Verapamil was left out of the assay and the cells were not kept on ice. The samples 
resuspended in HBSS instead of PBS and directly analysed with flow cytometry after 1, 1.5 
and 2hrs. The results are presented in figure 4.19, supplemental data for the figure can be 
found in appendix E. 
 
 
 
 
Figure 4.19 Rho123 efflux in RBE4 cells treated with 0, 5 ,10, 25, 50 and 250µM Verapamil 
measured by flow cytometry after 1, 1,5 and 2hrs. Untreated cells were set as baseline control 
and the results are presented as percent median fluorescent intensity (FI) of control. Each data 
point is the mean value ± standard deviation (n=3). 
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There was a rapid increase in Rhodamine efflux after 1.5 hrs, indicating that the P-gp pumps 
are efficiently pumping out Rhodamine in the absence of Verapamil inhibitor. The untreated 
control cells had initially more intracellular Rhodamine than in the previous Verapamil 
experiment. The median fluorescence decreased with time, but it did not reach the same low 
level even after 2hrs. The decrease in intracellular Rhodamine seemed to stabilize after 2hrs, 
but only one parallel of the samples had enough viable cells for analysis.  
4.4.5 Effect of siRNA consentration on Rho123 efflux 
 
In gene therapy application, the siRNA concentration plays a significant and limiting role in 
both polyplex stability and possible off-target effect. It was therefore of interest to investigate 
how far down on the concentration scale efficient knockdown was still apparent.  
 
Two dilution series were made with mdr1a and non-targeting siRNA respectively, prepared 
from an initial 96nM concentration after complexation with chitosan (N/P 30) by dilution 
with MQ water before 1:1 addition of hypertonic OptiMem. The resulting concentrations used 
were; 96, 48, 24, 12, 6 and 3nM. The cells were transfected as usual and after 48hrs subjected 
to rho123 influx and Verapamil inhibiton prior to flow analysis. The results are presented in 
figures 4.20 and 4.21, supplemental data for the figures can be found in appendix E. 
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Figure 4.20 Effect of siRNA concentration on Rho123 efflux in cells treated with chitosan DPn 
500 complexed with mdr1a-siRNA or nontargeting siRNA with an N/P ratio of 30. siRNA 
concentrations used were 96, 48, 24 12, 6 and 3nM.  Untreated cells were set as baseline control 
and the results are presented as percent median fluorescent intensity (FI) of control. Each data 
point is the mean value ± standard deviation (n=3). 
 
 
Figure 4.21 Overlay-plots of intracellular Rho123 fluorescence intensity in cells treated with 
chitosan DPn 500 complexed with mdr1a-siRNA or non-targeting siRNA in an N/P ratio of 30. 
siRNA concentrations used were 96, 48, 24, 12 and 6nM.  Results are presented as fluorescence 
intensity plotted against cell count (number of events). The cell count was set to 10000 events 
and measured through channel FL1. 
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It is evident from the results that the siRNA concentration affects the knockdown efficiency in 
a concentration-dependent manner (fig.4.19 and 4.20). It displays a decrease in median FI of 
~10 for each concentration division. However, when the concentration reaches 12,6 and 3nM, 
there is little observed difference between them and the untreated control. Interestingly, the 
Verapamil treated control samples failed to display any effect on the Rho123 retention in the 
cells, as seen in the preceding experiments. All of the non-targeting samples showed 
negligible deviations from the untreated control cells. 
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4.5 Doxorubicin accumulation in RBE4 cells visualized by CLSM 
 
Doxorubicin is a common cancer drug that works by intercalating the DNA in the nucleus and 
is also a known substrate of the P-gp pump.  The purpose of this experiment was to 
investigate the accumulation of Doxorubicin after transfection with mdr1a siRNA for 
inihibion of the p-gp pump.  The P-gp pump inhibitor Verapamil was included to compare the 
effects on Doxorubicin retention in the cells.  
 
Chitosans with DPn 400 and N/P 30 was chosen for investigation based on preliminary 
screening studies, the mdr1a siRNA was used for complexation based on the same studies. 
The cells were transfected as usual and the cells analysed by CLSM after 48hrs of incubation 
and treatment with 50 µM Doxorubicin and CellMask. The results are presented in figure 
4.21. 
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Figure 4.22 Doxorubicin accumulation in RBE4 cells 48hrs after transfection analysed by 
CLSM. A) untreated control cells  B) C) chitosan Dpn 400 complexed with non targeting-siRNA 
in  N/P ratio 30. CellMask plasma membrane stain is visualized as blue and Doxorubicin is 
presented as green fluorescence.  
 
The observed results are presented in figure 3.17 and show an increased accumulation of 
Doxorubicin in the cells treated with chitosan-mdr1a siRNA polyplexes compared to both 
control and non-targeting sample. Verapamil treated cells showed little difference from the 
untreated control cells, as previously seen in the siRNA concentration experiment.  
 
The fluorescence intensity of the chitosan-siRNA treated cells is variable, but with an overall 
higher amount of observed accumulated Doxorubicin. There is no directly observed nucleus 
localization of the Doxorubicin, and the accumulation is likely to reside in the endosomes.
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5. Discussion 
Chitosan is considered as a biocompatible and safe polymer for nucleic acid delivery and has 
been widely applied for pDNA, less research has been performed using siRNA. In this study, 
we set out to investigate the feasibility of using chitosan as a delivery vehicle for siRNA-
mediated knockdown of P-gp efflux pump in an in vitro model of blood brain barrier.  
 
P-glycoprotein (P-gp) was chosen as a target for RNAi mediated knockdown using chitosan 
as a novel delivery vehicle. P-gp is a highly clinically relevant target as it limits accessibility 
of drugs from the blood to the brain. The P-gp pump is a member of membrane transporters in 
brain endothelial cells which recognizes xenobiotics, extruding them from the cells. The P-gp 
pump is expressed by the mdr1 gene and downregulation of its expression could mediate drug 
accumulation in the cells. 
 
As the RBE4 cell line was not available at the start of this thesis, we started our work by 
screening of different chitosan/siRNA formulations in human lung cancer cells (H1299). We 
established suitable physiochemical characteristics of the chitosans like DPn and the N/P 
ratios of chitosan/siRNA complexes in both cell line. These preliminary studies were 
preformed with H1299 cells and the acquired knowledge was used with the RBE4 cells for 
further development.  
 
It was found that chitosans with a high DPn were efficient at both high and low N/P rations 
while low DPn chitosans were less efficient at low N/P ratio. Furthermore, the cytotoxicity 
profiling showed negligible effects on cell proliferation and activity. We managed developed 
a chitosan/siRNA polyplex delivery particle suitable for the targeting and downregulation of 
mdr1 mRNA and hence P-gp in rat brain endothelial cells in vitro.  
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5.1 Screening of DPn, N/P ratio and cytotoxicity in H1299 cells 
 
The need for optimization of chitosan length and charge interactions with nucleic acids have 
been verified by many studies (Koping-Hoggard et al. 2004; Lai and Lin 2009; Strand et al. 
2008) It was therefore evident to start the experiments by screening for the most efficient 
formulation of polyplexes by varying the DPn and N/P ratios of the linear chitosans.  
 
5.1.1 Uptake efficiency of chitosan/siRNA polyplexes in H1299 cells 
 
The first barrier encountered by the chitosan/siRNA polyplexes in vitro is binding to the 
cellular membrane and subsequent endocytosis. It has been suggested that chitosan of the 
appropriate Mw should be selected to achieve the desirable particle size because the 
transfection efficiency depends highly on the particle size which subsequently determines 
their cellular uptake (Mao et al. 2010). 
 
The level of cellular uptake of the chitosan polyplexes were determined by measuring 
fluorescently labeled Alexa siRNA in the transfected cells (fig 4.1). In general, there was an 
observed increase in fluorescence intensity using formulations with increasing DPn and N/P 
ratio. However, the chitosans with a low DPn seems to be dependent on a high N/P ratio for 
efficient uptake while the chitosans with a high DPn were just as efficient at low N/P ratios. 
This has also been shown by others where the use of a low N/P ratio seemed to function better 
with longer chitosans in transfection studies (Liao et al. 2010; Rojanarata et al. 2008).  
 
This could be due to poor physical stability of the nanoparticles at low N/P ratios leading to 
increased disassociation. This has previously been demonstrated by Liu et al (2007) where 
chitosans with a low Mw (10 kDa) resulted in the formation of large aggregates and almost no 
knockdown because it could not complex and compact siRNA into stable particles (Liu et al. 
2007) The reason for this may be a lack of sufficient charge interactions between the chitosan 
amino groups and the siRNA phosphate groups. It can be argued that the use of a low chitosan 
DPn and hence Mw together with a low N/P ratio with siRNA will lead to a further instability 
and disassociation.    
 
 63 
 
5.1.2 siRNA knockdown of GFP expression  
 
Uptake efficiency does not always equal knockdown efficiency, even though the 
nanoparticles enter the cells the siRNA needs to be liberated from the endosomes in order to 
exert its effect, so called uptake and release. Knockdown of the exogenously introduced GFP 
gene in H1299 cells was investigated by flow cytometry after transfection with and without 
addition of 10% serum.  
 
The results from transfection in serum-free medium (Optimem) showed an increasing 
downregulation of gene expression with increasing DPn and N/P ratio of the chitosan/anti-
GFP siRNA polyplexes (fig 4.3). Furthermore, there were minor observed differences 
between the N/P ratios for the longest chitosans. The cells treated with the lowest chitosan 
DPn and N/P ratios showed negligible effect on knockdown. These results correspond with 
the uptake experiment, confirming the importance of optimized polyplex formulation in 
regards to DPn and N/P ratio.  
 
Moreover, this result is in agreement with previously reported results where chitosan/anti-
GFP siRNA polyplexes showed an efficient GFP knockdown of  in H1299 (Howard et al. 
2006). Together, these results again indicate that chitosans with a high DPn are more efficient 
in mediating knockdown in H1299 cells and that low N/P ratios works better when the length 
of the chitosans are increased.  
 
5.1.3 Chitosan/siRNA polyplex stability in serum 
 
Development of siRNA delivery systems that are stable even in serum is very important for 
the practical applications of gene therapy in vivo (Mao et al. 2010). We wanted to investigate 
the possible effects of serum addition at transfection on knockdown efficiency in the H1299 
cells.  Earlier published studies has shown that chitosan nanoparticles were stable in medium 
containing up to 10% serum for chitosan–siRNA complexes (Katas and Alpar 2006). They 
also found that further incubation of the polyplexes in 50% serum rendered the siRNA stable 
against nucleases for several hours. 
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When the cultivated H1299 cells were transfected in presence of 10 % serum (fig 4.5), the 
chitosan/anti-GFP siRNA polyplexes with N/P ratios of 10 displayed a lower knockdown 
efficiency compared to the same samples in the serum-free transfection. This suggests that the 
serum had a slight negative effect on chitosan complexes with low N/P ratios. However, the 
chitosan polyplexes with N/P 30 displayed a comparable knockdown efficiency, although not 
to the same level. Together, these result show that the H1299 cells can be efficiently 
transfected in the presence of low serum concentrations. 
 
However, in regards to BBB application, the serum percentage in blood is normally ~55% 
(Manzone et al. 2007). Therefore, transfection studies with a higher concentration of serum 
addition should be performed to further establish stability of the chitosan/siRNA polyplexes.  
A recent study have shown that fluorescence fluctuation spectroscopy allows quantitatively 
monitoring of the disassembly of siRNA containing nanoparticles in full serum (Buyens et al. 
2010). This approach may be useful for further studies on the intravascular behavior of the 
chitosan/siRNA polyplexes.  
    
5.1.4 Knockdown of GAPDH expression  
 
To investigate the knockdown of an endogenous target beside GFP, GAPDH was chosen as a 
target for RNAi. The results of GAPDH knockdown in H1299 cells showed that the longest 
chitosans polyplexes (DPn 200/300) mediated similar downregulation of the enzyme, as well 
negligible difference between N/P ratio 10 and 30 (fig 4.7). The shortest chitosan displayed 
modest effect on knockdown, this again indicates that chitosans with DPn 54 is not sufficiently 
long enough to mediate optimal transfection efficiency, especially with a low NP ratio.  
 
Interestingly, the non-targeting samples displayed 10-25% reduction in apparent GAPDH 
expression. This may be due to non-specific effects of either the chitosan or the siRNA used 
and elucidates the need for investigation of possible cytotoxicity of the components. 
However, the experiments shows that the GAPDH assay worked well with the transfected 
H1299 cells and should also be compatible with the RBE4 cells.  
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When relating the results to the GFP experiments, the GAPDH knockdown did not display the 
same maximal effect, 90 and 85% respectively. Variance in protein half life may account for 
the observed differences, GFP is known to have a half life of 2hrs while GAPDH has a half 
life of 72 hrs (Franch et al. 2001; Howard et al. 2006). Since the cells were analysed 48 h after 
transfection, some GAPDH enzyme may still be present from before the transfection.  
 
The commercial transfection reagent Turbofect used in the experiments was very unstable in 
its knockdown and uptake efficiencies and was also seemingly toxic to the cells. This 
correlates with previously reported studies, where chitosan–DNA nanoparticles carried lower 
cytotoxicity than the commercial carriers such as Turbofect transfection reagents 
(Mohammadi et al. 2011).  
5.1.4 Cytotoxicity assays with H1299 cells 
 
Chitosans generally exhibit a good biocompatibility, it has been shown by several studies that 
chitosan/siRNA polyplexes display a low cytotoxicity (Corsi et al. 2003; M. Lee et al. 2001; 
Thanou et al. 2002). However, Liu et al (2007) found that chitosan/siRNA polyplexes with 
N/P ratios of 50 exhibited 20-40% cytotoxicity in H1299 cells. It is therefore important 
specifically investigate the possible cytotoxicity of the chitosan/siRNA polyplexes in the cell 
lines used.  
 
The chitosans chosen for these studies had a high DPn and were complexed with siRNA in 
low and high N/P ratios because of the increased possibility of toxic effect with a higher 
concentration of chitosan. It has been reported previously that excess chitosan in nanoparticles 
formed at high N/P may decrease cell viability related to the possible toxicity associated with 
high-molecular weight chitosan (Richardson et al. 1999). 
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The alamarBlue assay was used to determine if any changes in metabolic activity occurred 
over the 5-day period.  There was a negligible observed decrease in metabolic activity and no 
direct time-dependent decrease in activity (fig 4.8). The chitosan complexes displayed the 
same effect on knockdown as for naked chitosan. The samples treated with naked siRNA did 
not display the same decrease in metabolic activity, comparable to untreated control. The 
AlamarBlue assay has not been reported for use with chitosan/siRNA previously, a recent 
study did however evaluate the cytotoxicity of linear, selfbranced and trimethylated chitosan-
pDNA polyplexes in the HeLa cell line (Malmo et al. 2011). They found that the cells treated 
with linear chitosans retained a high metabolic activity with no significant changes.  
 
Evaluation of cell viability was done by propidium iodide-staining followed by flow analysis. 
PI is cell-impermeable and therfore only dead cells with damaged/disintegrated cell 
membranes will be stained. The results showed an increasing PI permeability over the first 
three days with a decline the next two days (fig 4.9). Chitosan with N/P ratio 60 showed the 
same level of cell death for both siRNA complexes and naked chitosans. RNAiMAX resulted 
in the highest level of PI-positive cells, and thus correlates with the alamarBlue assay. The 
observed decline in cell permeability the last two days may be attributed to the growth of new 
and viable cells which are not affected by the initial transfection procedure. This would then 
compete for the number of PI-positive cells, resulting in a “false” observed decrease in 
permeability.  
 
Investigation of cell proliferation was studied by cell counting (fig 4.10) and reflected the 
results seen in the previous cytotoxicity assays. The chitosan complexes showed similar 
growth retention while naked siRNA gave comparable results to the untreated control cells.  
This is expected since naked siRNA is subject to degradation by endogenous enzymes, and is 
too large and too negatively charged to cross cellular membranes (Whitehead et al. 2009). 
Cells treated with RNAiMAX complexes had the greatest growth retention, again suggesting 
toxic nature of the transfection reagent. 
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The BCA assay was used to estimate the concentration of protein in the samples by 
comparison with a standard curve based on absorbance readings. The samples gave 
comparable results to the cell count, with a linear increase in protein concentration reaching a 
small plateau at the end of five days (fig 4.11). This also corresponds to the metabolic activity 
and PI staining with a similar effect of chitosans and RNAiMAX resulting in the greatest 
reduction.  
 
The commercial transfection reagent RNAiMAX had the most pronounced effect in all the 
assays, indicating that the reagent is more toxic to the cells. This has been shown in other cell 
lines where RNAiMAX resulted in a 1/3 decrease in cell growth relative to novel delivery 
lipids (NDL’s) and untreated controls at 1/4 of the recommended concentration (Rossomando 
2010). In summary, the four different cytotoxicity assays all displayed comparable negligible 
effects of the naked chitosan and chitosan/siRNA complexes on the H1299 cells. The subtle 
changes observed may be attributed to the growth of new cells, exceeding the surface layer 
capacity and thus restricting metabolic activity, proliferation and hence protein concentration 
at the end of the five days.  
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5.2 Screening of DPn , N/P ratio and cytotoxicity in  RBE4 cells 
 
The previous transfection studies on H1299 cells set the basis for development of 
chitosan/siRNA polyplexes that efficiently transfected the RBE4 cells. The experiments 
started with screening of general uptake and knockdown efficiency of the selected 
chitosan/siRNA polyplexes as well as its cytotoxicity.  
 
The aim of the following sections was to specifically downregulate the mdr1a/b mRNA which 
codes for the P-glycoprotein pump in brain endothelial cells. We investigated the effect of 
mdr1a siRNA on drug efflux in the RBE4 cells using two functional assays; Rhodamine 123 
efflux by flow cytometry and visualization of the anticancer drug Doxorubicin by CLSM. 
5.2.1 Uptake of chitosan/siRNA polyplexes in RBE4 cells 
 
In order to establish efficient uptake of polyplexes into the RBE4 cells, fluorescent Alexa 
siRNA was used (fig 4.12). The results showed increasing uptake efficiency with higher DPn 
and N/P ratios which correlated with the previous mentioned studies with H1299 cells (fig. 
4.1). There were however a greater difference between the effects of N/P ratios when using 
the same chitosan, this is expected since the ratios are 10 and 60 as opposed to 10 and 30 used 
with the H1299 cells.  
 
All chitosans with different high DPn values displayed similar efficiencies when complexes in 
N/P ratios of 60, indicating that the chitosan length plays a minor part in mediating 
transfection when using high N/P ratios.  The chitosan with DPn 810 did however not display 
the same uptake efficiency as the others, indicating that the chitosan was compromised in 
some way before or during the transfection. Altogether, the results indicated efficient uptake 
of chitosan/siRNA polyplexes in the RBE4 cell line. 
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5.2.2 GAPDH knockdown in RBE4 cells 
 
The observed result from knockdown in RBE4 cells showed nearly 1/2 reduction in enzyme 
expression for chitosans with high DPn complexed in N/P ratio 30. However, only negligible 
reduction in enzyme activity was observed for formulations with N/P 10, this can again be 
attributed to a lower stability of the polyplexes. However, this is not comparable to the high 
DPn chitosans in H1299 cells, where both NP 10 and 30 exhibited similar effect on 
knockdown (fig 4.7).   
 
Direct conclusions can however not be drawn by comparing different cell lines, they may 
possess different uptake and cellular processing of the polyplexes (Malmo et al. 2011) 
Furthermore, aggregates, enodocytic mechanisms and intracellular trafficking may influence 
the uptake efficiency. Taken together, these studies confirm efficient uptake and knockdown 
ability of the chitosan/siRNA complexes in RBE4 cells. It may however be speculated that 
polyplexes formulated with low N/P ratios are not as efficient in transfecting the RBE4 cell 
line, despite using chitosan with a high DPn. 
 
5.2.3 Cytotoxicity of siRNA-chitosan nanoparticles on RBE4 cells 
 
By measuring the reduction in metabolic growth using the alamarBlue assay, cytotoxicity of 
chitosan nanoparticles, naked chitosan and siRNA was investigated in RBE4 cells (fig 4.14). 
The results showed comparable values to that of the H1299 cells with a maximum reduction 
with chitosan nanoparticels of ~20% of untreated control. The commercial RNAiMAX 
displayed an even greater reduction than the chitosan/siRNA polyplexes, again reflecting the 
toxic nature of the transfection reagent. These result correlates with the previous study in 
H1299 cells, where the chitosans with the highest DPn complexed with non targeting siRNA 
at N/P ratio 60 had a maximum observed reduction in metabolic activity. 
 
Taken together, the chitosans used throughout this thesis seems to exhibit tolerable toxicity in 
both the H1299 and RBE 4 cell lines. The observed concentration effect of the chitosans 
indicates a need for using a minimum N/P ratio in further development of polyplexes.  
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5.3 Rhodamine efflux in RBE4 cells  
 
We needed a functional assay for estimation of P-gp knockdown. Rhodamine is a well known 
substrate for the P-gp pump and by investigating its intracellular accumulation in cells we 
could determine the knockdown effect of chitosan-mdr1a/b polyplexes. In order to establish 
effective gene knockdown of the P-gp pump in vitro, the Rhodamine efflux in transfected 
cells were compared to Verapamil positive control which have been studied by others 
(Kasinathan et al. 2010; Pautina 2010).  
 
Only the mdr1a siRNA displayed an effect on Rhodamine efflux, mdr1b siRNA had no 
apparent effect compared to untreated control (fig 4.15). Even though the mdr1b has been 
showed to be upregulated in cultured RBE4 cells (Loscher 2005), it did not seem to be 
functional in this study. This may be attributed to the localization of the mrd1b gene which 
primarily resides in the astrocytes (Begley et al. 2000).  
 
The chitosan/mdr1 polyplexes were formulated with an N/P ratio of 10, even though low N/P 
ratios have shown to work well with high DPn chitosans, they may be unstable and higher 
ratios should be investigated. The cytotoxicity studies showed negligible negative effects at 
N/P 60, thus increasing the chitosan concentration should not compromise cell viability.  
 
Furthermore, Rhodamine has also been suggested to be a substrate for the multidrug 
resistance protein Mrp1 (Minderman 1996; Twentyman et al. 1994; Zaman et al. 1994). Mrp1 
protein, mRNa and activity has been shown to be upregulated in rat or human endothelial cell 
lines during culture (Regina et al. 1998; Seetharaman et al. 1998). Because Verapamil is a 
known inhibitor of both P-gp and Mrp1 (Loscher 2005), it can be suggested that the effect of 
Rhodamine retention in the cells not treated with the inhibitor is counteracted by the efflux by 
Mpr1. This indicates the need for further study on the possible anti synergistic effects of the 
two mRNAs.  
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The median fluorescent intensity of chitosan/mdr1a-siRNA treated cells did however not 
reach the same level as for Verapamil control. This indicated the need for siRNA dosage-
experiments as well as Verapamil concentration investigation for assay adjustment. Pautina et 
al (2010) performed a similar experiment where Vepapamil displayed a much more 
pronounced effect on intracellular accumulation than the siRNA mediated knockdown, using 
the same concentration of the inhibitor (Pautina 2010). 
 
We wanted to look further into the use of Verapamil as a positive control in the Rho123 
assay. When the Verapamil concentration effect was investigated it showed a linear increase 
in intracellular Rhodamine accumulation (fig 4.17). This has also been shown by another 
study where addition of Verapamil significantly increased R123 uptake in a concentration-
dependent manner (Yang 2010). This suggests that the Rhodamine 123 efflux assay is highly 
dependent on Verapamil concentrations and makes it difficult to compare the results with 
previous publications.  
 
We also wanted to measure the rate of efflux using the same concentrations by excluding ice 
and post-Rho123 efflux incubation from the assay. The results showed a rapid decline in 
intracellular Rhodamine with time for all concentrations and increasing dell death which 
confirmed the need of ice (fig 4.19). The untreated control cells also contained Rhodamine 
which graduately became depleted; this is probably due to the lack of incubation after 
treatment with Rhodamine. The untreated cells have functional P-gp pumps and may not have 
enough time to pump the Rhodamine out before analysis, therefore resulting in higher values 
than previously seen. Also, a high sample number limited the measurements since the cells 
died over time in the absence of ice.  
 
Furthermore, the siRNA concentration is a limiting factor in clinical applications of RNAi. 
Throughout the work presented in this thesis, we used a constant siRNA concentration of 
45nM, commonly used siRNA concentrations in published studies is 50nM (Dehousse et al. 
2010; Tahara et al. 2010). The possibility of off-target or non-spesific effects increases when 
excess amounts of siRNA are delivered to the body. A major problem with increasing the 
siRNA concentration in the polyplex formulations for transfection is the increased excess of 
siRNA that may interfere with uptake and induce immunological responses.  
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We therefore investigated the knockdown efficiency of the P-gp pump at different mdr1a-
siRNA concentrations to determine a minimum concentration for sufficient knockdown.  
The results reflected a linear decrease in knockdown for each 1:2 dilution from 96nM to 
12nM where it reached a halt and did not change significantly between 12, 6 and 3 nM (fig 
4.20). The three lowest concentrations did not display more than ~5% knockdown compared 
to the untreated control cells, this suggest that a minimum threshold for siRNA concentration 
lies between 48 and 12nM for this particular chitosan.  
 
Taken together, the Rho123 assay reflected a 2-3 fold increase in intracellular accumulation 
after introduction of mdr1a siRNA compared to untreated control. This confirms knockdown 
of the mRNA coding for the P-gp pump but needs further development for sufficient effect. 
Verapamil is a strong inhibitor of the P-gp pump directly, but also other transporters in the 
endothelial cell membranes. This makes it difficult to compare the effect on cells treated with 
chitosan/siRNA polyplexes with Verapamil treated cells.  
 
5.4 CLSM analysis of Doxorubicin accumulation in RBE4 cells. 
 
The anticancer drug Doxorubicin works by intercalating with DNA in the nucleus and is also 
a known substrate of the P-pg pump (Loscher 2005). By visualizing the intracellular 
accumulation of Doxorubicin in cells by CLSM, it was possible to determine efficient 
knockdown of P-gp and resulting retention of the drug.  
 
The results in reflected an increased accumulation of Doxorubicin in cells treated with 
chitosan-mdr1a siRNA polyplexes, confirming knockdown of P-gp (fig 4.22). It was difficult 
to determine whether the Doxorubicin is located in the nucleus or still residing in the 
endosomes, this could have been resolved by additionally staining of the nucleus membrane.  
Unfortunately, it was not possible to compare the results with the Verapamil treated cells; 
there is a possibility that the stock solution of Verapamil was too old or compromised in some 
way. Even though the Verapamil inhibition failed to work, the difference in Doxorubicin 
accumulation between chitosan/mdr1a-siRNA transfected cells and untreated control cells still 
gives a good indication of efficient knockdown. 
 
 
 73 
 
 
Like Rhodamine, Doxorubicin is also a common substrate of the MDR transporter MRP1 
which resides in the RBE4 cells (Loscher 2005). This can possibly be working as an 
additional efflux mechanism and thus counteract the effect of reduced P-gp expression in the 
cells. It once again shows the substrate-overlap between the two MDR transporters and poses 
an additional problem of efficient retention. Verapamil is also an inhibitor of MRP1, so the 
drug retention in the cells treated with the inhibitor was expected to be higher.  
 
Throughout this thesis we have used functional assays that indicate that the P-gp function is 
disabeled. However, we have no direct evidence for knockdown. In order to confirm the 
findings, western blot or immunostaining for protein determination and PCR for mRNA 
expression should be performed. It must be taken into consideration that the RBE4 cells 
expresses very low levels of P-gp in culture (Hosoya et al. 2000), therefore these studies are 
yet to be successful in our research group. 
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5.6 Summary  
 
The chitosan/siRNA polyplex formulations used throughout this thesis displayed an efficient 
uptake and knockdown as well as low cytotoxicity in both H1299 and RBE4 cells.  
- There was an observed correlation between chitosan DPn and N/P ratios of polyplexes 
on both uptake and knockdown efficiency. Chitosans with a low DPn generally needed 
a high N/P ratio while chitosans with higher DPn worked well at low N/P ratios.  
- The H1299 cells were transfected efficiently in the presence of serum, although 
knockdown levels were lower at low N/P ratios  
- The chitosan/siRNA polyplexes exhibited negligible cytotoxicity in both cell lines at 
high N/P ratios.  
The P-gp expression in RBE4 cells were efficiently downregulated after chitosan-mdr1a-
siRNA transfection, but not mdr1b. 
- Rhodamine accumulation in the RBE4 cells increased 2-3 fold in chitosan/mdr1a-
siRNA transfected cells compared to untreated control cells. 
- Verapamil inhibition was too efficient to compare with chitosan transfection, possibly 
due to dual inhibition. It also displayed a concentration and time dependent efficiency 
on Rhodamine accumulation. 
- The mdr1a-siRNA concentration was a limiting factor in the knockdown of P-gp, a 
minimum concentration for efficient knockdown was found to lie between 12-48nM. 
- The visualization of intracellular Doxorubicin in the RBE4 cells gave a good 
indication of efficient reduction in P-gp expression in cells transfected with 
chitosan/mdr1a-siRNA. 
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6. Concluding remarks 
We have shown that chitosan can be used as an efficent delivery vehicle for siRNA in both 
H1299 and RBE4 cells with negligible cytotoxicity in vitro. The formulated chitosan/siRNA 
polyplexes was found to dependent on DPn and N/P ratios in order to exert maximal effect on 
both uptake and knockdown.  
 
Specifically, we managed to downregulate the P-gp expression in RBE4 cells using chitosans 
with high a DPn complexed with mdr1a-siRNA in a low N/P ratio. Together, the results 
presented in this thesis elucidate the potential of chitosan mediated siRNA downregulation of 
the P-gp pump in RBE4 cells and further development for in vivo applications.    
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7. Future directions and considerations 
There is still much to be revealed about the chitosan/siRNA polyplexes in general and in 
relation to blood brain barrier and P-plycoprotein applications in vitro. Furthermore, 
modifications to the proposed delivery system may be needed for use in vivo. 
 
7.1 Chitosan/siRNA polyplexes 
 
In order to quantitatively confirm mRNA and protein reduction after administration of 
chitosan/siRNA polyplexes, PCR and western blot/immunohistochemical staining needs to be 
performed. For evaluation of possible off target effects, a wide microarray analysis of gene 
expression can give a more accurate picture. 
 
When these parameters are firmly established, testing in vitro using animal models like rat or 
mice can be performed. However, chitosan/siRNA polyplexes are in need of further 
development for in vivo applications and targeting to tissue. Structural modifications like 
copolymerization and functional group modification or ligand conjugation may be beneficial 
in increasing transfection and uptake efficiency as well as steric stability and serum 
compatibility.  
 
Nanoparticles that are polycation-nucleic acid composites are known to be unstable in 
biological fluids such as blood. One method of preventing self-aggregation and undesired 
interactions with unwanted components in biological fluids is to employ steric stabilization.  
Polythethylene glycol (PEG) has been conjugated to different non-viral delivery carriers, and 
the resulting PEGylated particles have demonstrated increased salt and serum stability (Jiang 
et al. 2007). Another means of copolymerization is Polyethyleneimine (PEI), which also has 
been used as a modifier for chitosan vector derivation but can exhibit high toxicity to cells 
and is need for further optimization (Wong et al. 2005). 
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Many of the nanoparticles developed cannot be used in clinical settings due to nonspecific 
delivery, which may lead to unwanted side effects. Preferably, the delivery system should 
show enhanced concentrations of therapeutic payloads at disease sites, minimize concerns 
about off-target effects, and ultimately raise the therapeutic index (Han et al. 2010; Whitehead 
et al. 2009). Therefore, introduction of targeting ligands may increase the specificity and 
safety of the delivery agent. A novel tumor targeted delivery system for siRNA has recently 
been demonstrated by using an Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle for 
selective intratumoral delivery by binding to the ανβ3 integrin (Han et al. 2010) 
 
7.2 P-gp and the blood brain barrier 
 
Knockdown of efflux pumps such as P-gp is very important in cancer treatment because many 
cancer types become resistant to cytostatic drugs in their presence. By downregulating their 
expression we can dramatically improve the medical treatment. As previously mentioned, 
more information regarding the disassembly of chitosan/siRNA polyplexes in blood needs to 
be established for applications in viro. It can be suggested that to overcome the BBB, one 
should develop a chitosan nanoparticle that targets more than one transporter, by combining 
several siRNAs. A drawback from this approach may be the increased access of harmful toxic 
substances to the brain when shutting down several MDR proteins.  
 
Another approach could be to engineer nanoparticles with dual drug and siRNA delivery, 
previously shown in a cancer cell line (Meng et al. 2010). In this regard the P-gp expression 
has a long half-life of about 16-72 hrs depending on cell line (Stierlé 2004), which ultimately 
raises the question of whether the existing P-gp would pump out the drug before efficient 
knockdown occurs. Furthermore, it brings into question what the optimal transfection duration 
is in order to reach satisfactory knockdown of P-gp expression before administration of a 
drug. Kinetic studies needs to be performed to investigate the temporal effects of 
chitosan/siRNA delivery in cells. Moreover, the possible off target effects and cytotoxicity 
need to be evaluated in order to apply the current knowledge to in vivo testing. 
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Additionally, there may be a functional impact of polymorphisms in the human MDR1 gene, 
there has been reported more than 50 single nucleotide polymorphisms and 
insertion/deletions, some associated with alteration of P-gp expression and/or function 
(Brinkmann and Eichelbaum 2001; Löscher and Potschka 2005) This poses an additional 
limitation of the RBE4 cell line model, because is not known whether functionally relevant 
polymorphisms also occurs in the mdr1a gene (Löscher and Potschka 2005; Volk and Löscher 
2005). These polymorphisms may lead to inter-individual or ethnicity differences in responses 
and should be taken into account in an in vitro application.  
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A Production numbers  
Table 1. Producers and production numbers of the materials used. 
 
Water, Mol biograde – Dnase, RNase and 
protease free 
250010 5prime Propidium Iodide 81845 Sigma 
DPBS, Dulbecco’s phosphate buffered saline 14190-094 Gibco Alexa fluor® 647 siRNA  Molecular Probes
TM 
DMEM, Dulbecco’s modified eagle medium,  31053-028 Gibco GFP (eGFP) siRNA AM4626 Ambion 
HBSS, Hank’s balanced salt solution,  14025-050 Gibco Negative control siRNA 4611G  
Trypsin/EDTA (0,25%/0,02%)  T-4049 Sigma GAPDH (human) siRNA AM605 Ambion 
OptiMEM ® reduced serum medium  31985-062 Gibco GAPDH (human, mouse, rat) 
siRNA 
AM4624 Ambion 
Mannitol 103304Y AnalaR®  Abcb1a/b siRNA 4390771 Ambion 
HEPES H-3375 Sigma BCA protein assay kitTM 71285-3 Pierce 
RPMI-1640 medium  Sigma KDalertTM GAPDH assay kit 1639 Ambion 
PEST, penicillin and streptomycin P-0781 Sigma alamarBlue® assay kit DAL 1025 Biosource, Invitrogen 
G418 disulfate salt solution A1720-1G Sigma 
FBS, Fetal bovine serum  10106-169 Gibco 
NEAA, non-essential amino acids  11140-035 Gibco 
αMEM medium 31095-029 Gibco 
BD biocoatTM collagen cell culture flasks  354462 BD biosciences 
BD BiocoatTM collagen 96 well plates ref# 354407 BD biosciences 
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B Formulation of polyplexes 
 
The formulation of transfection mixtures was calculated for 4 or 6 wells using table 2 given below. Calculation is based on the following 
relationship:  
- Conc siRNA in polyplexes, 1.2 µg/mL = 90.2 pmol/mL = 90.2 nM before hypertonic OPTImem addition; dose 30ng/well (2.25pmol)  
- Polyplex of N/P =1 corresponds 0.584 mg chitosan (Fa 0) per 1 mg siRNA 
 
Table 2 Polyplex formulation for 4 wells in 96-well plates. 
 
N/P ratio 10 20 30 40 60 
siRNA (µL), 66.5 
ug/mL 
2.26 2.26 2.26 2.26 2.26 
Chitosan(µL), 0,1 
mg/mL 
8.76 17.52 26.29 35.05 52.57 
MQ water (µL) 113.98 105.22 96.46 87.69 70.17 
Total 125.00 125.00 125.00 125.00 125.00 
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C Uptake and knockdown in H1299 and RBE4 cells 
 
C.1  Alexa 647 uptake in RBE4 and H1299 cells 
 
Table 3. Raw flow cytometry data for Alexa 647 Uptake in H1299 cells. 
Sample Ctrl C54 T C54 T C200 T C200 T C300 T C300 T Turbo T siRNA 
N/P  10 30 10 30 10 30 3 - 
 Parallell          
Median FI 
1 0.665 10.10 36.70 39.80 75.40 95.3 89.00 43.2 0.77 
2 0.671 8.95 48.10 44.80 60.20 88.7 98.80 67 0.83 
avg 0.67 9.53 42.40 42.30 67.80 92.00 93.90 55.10 0.80 
stdev 0.00 0.81 8.06 3.54 10.75 4.67 6.93 16.83 0.04 
 
Table 4. Raw flow cytometry data for Alexa 647 Uptake in  RBE4 cells. 
Sample C 250 C 250 C 300 C 300 C 400 C 400 C 810 C 810 siRNA ctrl 
 Parallell 10 60 10 60 10 60 10 60 -  
Median FI 
1 69.1 177 101 214 125 205 12.3 143 1.43 1.74 
2 53.1 148 110 190 149 174 9.79 138 1.4 1.31 
3 47.7 * * 165 168 210 11.4 159 1.42 1.89 
avg 56.63 162.50 105.50 189.67 147.33 196.33 11.16 146.67 1.42 1.65 
std 11.13 20.51 6.36 24.50 21.55 19.50 1.27 10.97 0.02 0.30 
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Figure 3. Alexa647 uptake in H1299 cells, siRNA control. 
 
Figure 4. Alexa 647 uptake in H1299 cell treated with chitosan DPn 300 complexed with siRNA at N/P ratio 30 
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Figure 5. Uptake in RBE4 cells, Alexa647-siRNA control 
 
Figure 6. Uptake in RBE4 cells treated with chitosan Dpn300 complexed with Alexa647-siRNA in N/P ratio 30. 
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C.2 GFP knockdown in H1299 cells 
 
 
 
Table 5. Raw and calculated flow cytometry data for H1299 GFP knockdown without serum incubation.  
 
 
GFP Knockdown without serum 
Sample  Ctrl C 54 (T) C54 
(NT) 
C 200 (T) C200 
(NT) 
C 300 (T) C300 
(NT) 
Turbofect T Turbofect 
NT 
N/P   10 30 30 10 30 30 10 30 30 3 3 
 Parallell             
 
Median FI 
1 19.9 18.90 5.51 16.50 5.81 1.25 20.70 1.77 2.18 21.60 20.8 26.10 
2 18.9 18.00 5.46 18.50 4.85 1.23 20.80 7.02 2.56 22.20 22.6 24.50 
3 20.7 17.90 5.17 17.10 * 2.63 20.80 4.64 1.96 22.00 23 * 
 
% median FI of 
ctrl 
1 100.34 95.29 27.78 83.19 29.29 6.30 104.37 8.92 10.99 108.91 104.87 131.60 
2 95.29 90.76 27.53 93.28 24.45 6.20 104.87 35.39 12.91 111.93 113.95 123.53 
3 104.37 90.25 26.07 86.22 0.00 13.26 104.87 23.39 9.88 110.92 115.97 0.00 
avg  100.00 92.10 27.13 87.56 17.92 8.59 104.71 22.57 11.26 110.59 111.60 127.56 
stdev  4.55 2.78 0.93 5.17 15.70 4.05 0.29 13.25 1.53 1.54 5.91 5.70 
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Table 6. Raw and calculated flow cytometry data for H1299 GFP knockdown with serum incubation. 
 
 
GFP knockdown with serum 
Sample  Ctrl C 54 (T) C54 
(NT) 
C 200 (T) C200 
(NT) 
C 300 (T) C300 
(NT) 
Turbofect 
T 
Turbofect 
NT 
N/P   10 30 30 10 30 30 10 30 30 3 3 
 Parallell             
 
Median FI 
1 11.3 14.9 13.4 14.7 13.4 4.05 11.1 15.2 1.69 15.6 8.63 10.6 
2 11.8 14.7 12.4 14.4 13.2 4.28 11 15.5 1.92 15.8 8.63 9.97 
3 10.6 14.2 11.6 14.2 13.4 3.91 11.1 14.9 1.89 14 8.71 8.95 
 
% median FI of 
ctrl 
1 100.59 132.64 119.29 130.86 119.29 36.05 98.81 135.31 15.04 138.87 76.82 94.36 
2 105.04 130.86 110.39 128.19 117.51 38.10 97.92 137.98 17.09 140.65 76.82 88.75 
3 94.36 126.41 103.26 126.41 119.29 34.81 98.81 132.64 16.82 124.63 77.54 79.67 
avg  100.00 129.97 110.98 128.49 118.69 36.32 98.52 135.31 16.32 134.72 77.06 87.60 
stdev  5.37 3.21 8.03 2.24 1.03 1.66 0.51 2.67 1.11 8.78 0.41 7.41 
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Figure 1. GFP expression in untreated control cells. 
 
Figure 2. GFP expression in cells treated with Chitosan DPn 300 complexed with GFP siRNA at N/P ratio 30. 
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C.3 GAPDH knockdown in H1299 cells and RBE4 cells 
 
Table 7.  Raw and calculated data for GAPDH knockdown in H1299 cells. 
 
Sample C54 C54 C54 NT C200 C200 C200 NT C300  C300  C300 NT Turbo T  Turbo NT Ctrl Blank 
N/P 10 30 30 10 30 30 10 30 30 - - - - 
  Parallell                           
Abs 
615nm 
1 0.154 0.355 0.168 0.471 0.535 0.205 0.524 0.537 0.260 0.621 0.647 0.087 0.666 
2 0.229 0.385 0.187 0.559 0.552 0.325 0.531 0.530 0.231 0.523 0.658 0.177 0.656 
3 0.191 0.385 0.221 0.558 0.589 0.300 0.483 0.537 0.216 0.661 0.584 0.179 0.738 
 
 
Minus 
blank 
1 -
0.532 
-
0.332 
-0.519 -
0.215 
-0.151 -0.481 -0.163 -0.150 -0.427 -0.066 -0.039 -0.599  
2 -
0.458 
-
0.301 
-0.499 -
0.128 
-0.134 -0.362 -0.155 -0.157 -0.455 -0.163 -0.028 -0.509  
3 -
0.495 
-
0.301 
-0.466 -
0.129 
-0.097 -0.387 -0.204 -0.149 -0.470 -0.025 -0.103 -0.507  
% 
reduced 
of ctrl 
1 98.83 61.57 96.29 39.92 28.05 89.38 30.25 27.76 79.19 12.24 7.32 111.25  
2 84.96 55.96 92.72 23.67 24.88 67.16 28.83 29.09 84.55   5.27 94.56  
3 91.94 55.89 86.43 23.88 18.03 71.80 37.84 27.66 87.34 4.64   94.19  
Avg 91.91 57.80 91.81 29.16 23.65 76.11 32.31 28.17 83.69 8.44 6.29 100.00  
Std 6.93 3.26 4.99 9.32 5.12 11.72 4.84 0.80 4.14 5.37 1.44 9.75  
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D Cytotoxicity data  
 
D.1 Alamar blue Assay calculations and data   
 
To determine the percent reduction of alamarBlue, the following equation was used: 
 
% Reduced      = CRED Test Well 
                 COX Negative Control Well 
 
                 =  (εOX)λ2 Aλ1 - (εOX) λ1 Aλ2             x 100   
                    (εRED)λ1 A’λ2 - (εRED)λ2 A’λ1 
 
eg:         = (117,216)(.61) – (80,586)(.42)   x 100   
                   (155,677)(.64) – (14,652)(.44) 
 
                =        71,502 – 33,846     x 100   
                            99,633 – 6,447 
 
                =      0.404 x 100 = 40% 
 
Where:  
 
CRED = concentration of reduced form alamarBlue 
COX = oxidized form of alamarBlue 
λ1 = 570, λ2 = 600 
(εOX)λ2 = 117,216 molar extinction coefficient of alamarBlue oxidized form  
(εOX)λ1 = 80,586 molar extinction coefficient of alamarBlue oxidized form  
(εRED)λ1 = 155,677 molar extinction coefficient of alamarBlue reduced form  
(εRED)λ2 = 14,652 molar extinction coefficient of alamarBlue reduced form  
Aλ1 = 0.61 ,absorbance reading for test well 
Aλ2 = 0.42 ,absorbance reading for test well 
A’λ2 = 0.64 ,absorbance reading for negative control well 
A’λ1 = 0.44 ,absorbance reading for negative control well. 
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Table 8.1 Raw absorbance and calculated values from 5-days alamarBlue assay with H1299 cells. 
 
Time 24hrs 48hrs 72hrs 
Sample Ctrl  C 200  C 200  C 200 
(N) 
siRNA R-
MAX 
Ctrl  C 200  C 200  C 200 
(N) 
siRN
A 
R-
MAX 
Ctrl  C 200  C 200  C 200 
(N) 
siRNA R-
MAX 
N/P - 10 60 60 - - - 10 60 60 - - - 10 60 60 - - 
  
Parallell 
                                    
A
b
s
 5
7
0
 
1 0.674 0.683 0.589 0.605 0.666 0.640 1.259 1.037 0.936 0.930 0.908 0.890 1.890 1.305 1.166 1.154 1.033 0.971 
2 0.938 0.838 0.826 0.843 0.737 0.743 1.062 1.023 1.017 1.015 1.210 1.010 1.053 0.985 0.972 0.984 0.949 0.976 
3 0.761 0.885 0.743 0.779 0.808 0.760 1.017 0.936 0.981 0.890 0.939 0.965 1.034 0.924 0.951 0.950 0.945 0.909 
4 0.880 0.842 0.882 1.004 0.851 0.661 0.965 0.979 0.900 0.930 0.953 0.960 1.049 0.994 0.972 1.010 1.022 1.058 
A
b
s
 6
0
0
 
1 0.393 0.448 0.422 0.418 0.481 0.430 0.705 0.318 0.301 0.293 0.339 0.315 1.241 0.576 0.504 0.507 0.355 0.354 
2 0.525 0.572 0.563 0.576 0.557 0.536 0.321 0.352 0.359 0.354 0.451 0.324 0.300 0.347 0.321 0.350 0.336 0.334 
3 0.511 0.577 0.516 0.540 0.590 0.523 0.319 0.361 0.352 0.367 0.431 0.329 0.361 0.357 0.363 0.361 0.392 0.350 
4 0.608 0.566 0.489 0.636 0.551 0.516 0.292 0.329 0.350 0.379 0.375 0.346 0.250 0.322 0.297 0.289 0.324 0.279 
%
 r
e
d
u
c
e
d
 o
f 
c
tr
l 
1  * 78.55 73.10 58.19 61.81 65.32 90.56 104.2 * 98.09 97.97 90.85 102.3 * * * 113.19 * 
2 109.7 * * * * * 110.1 * 109.36 107.8 108.1 * 105.8 * 105.70 106.4 105.29 101.63 
3 90.28 92.48 110.1 87.61 92.09 90.77 99.28 107.1 92.47 99.44 85.79 86.43 91.82 108.02 93.32 96.48 96.50 92.87 
4  * * 110.3 * * 115.1 * 73.82 92.47 * * 67.13 * 74.42 65.58 65.16 68.85 67.88 
avg 100.0 85.51 97.87 87.61 97.32 90.41 100.0 95.07 98.10 101.8 97.29 81.47 100.0 91.22 88.20 89.36 95.96 87.46 
std 13.75 9.85 21.45 20.80 38.39 24.91 7.69 18.46 9.75 5.30 11.17 12.61 7.29 23.76 20.55 21.54 19.31 17.51 
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Table 8.2 Raw absorbance and calculated values from 5-days alamarBlue assay with H1299 cells. 
 
Time   96hrs 120hrs 
Sample Ctrl  C 200  C 200  C 
200 
(N) 
siRNA R-MAX Ctrl  C 200  C 200  C 200 
(N) 
siRNA R-MAX 
N/P - 10 60 60 - - - 10 60 60 - - 
  Parallell                         
A
b
s
 5
7
0
 
1 0.840 1.150 0.863 1.280 1.027 1.221 0.733 0.621 0.613 0.833 0.614 0.594 
2 0.884 0.802 0.857 0.871 0.828 0.837 0.609 0.589 0.629 0.670 0.574 0.606 
3 0.916 0.876 0.878 0.854 0.836 0.846 0.614 0.743 0.623 0.631 0.532 0.611 
4 0.854 0.873 0.862 0.883 0.819 0.841 0.632 0.615 0.625 0.636 0.596 0.605 
A
b
s
 6
0
0
 
1 0.474 0.717 0.473 0.826 0.753 0.802 0.234 0.210 0.217 0.247 0.215 0.196 
2 0.519 0.543 0.550 0.574 0.594 0.541 0.235 0.197 0.219 0.222 0.225 0.211 
3 0.533 0.556 0.551 0.575 0.630 0.543 0.217 0.231 0.203 0.213 0.197 0.214 
4 0.531 0.554 0.531 0.549 0.599 0.549 0.211 0.199 0.212 0.203 0.208 0.200 
%
 r
e
d
u
c
e
d
 o
f 
c
tr
l 
1 132.15 101.53         101.99   105.74 102.96     
2 91.74 103.89 84.37 94.47 93.98 82.66 100.93 98.14 99.29 104.79 113.38 91.81 
3 93.92 108.91 97.97 98.92 91.02 80.02 94.68 94.77 119.31 98.58 98.79 80.97 
4 82.18 86.66 87.41 88.05 89.68 72.34 102.40 106.68 119.31 105.03 108.69 99.22 
avg 100.00 100.25 89.92 93.82 91.56 78.34 100.00 99.86 110.91 102.84 106.95 90.67 
std 22.03 9.56 7.14 5.47 2.20 5.36 3.60 6.14 10.04 2.99 7.45 9.18 
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Table. 8.3 Raw and calculated data for metabolic activity in RBE4 cells. 
 
Sample C 200  C 200 NT C 300 C 300 NT RNAiMAX siRNA ctrl triton blank 
N/P 10 60 60 10 60 60 - - - - - 
  Parallell                       
Abs 570 
nm 
1 0.5937 0.563 0.5916 0.5792 0.5597 0.5897 0.5776 0.6124 0.5959 0.3854 0.622 
2 0.5802 0.5592 0.5807 0.6081 0.5648 0.583 0.5667 0.6106 0.6214 0.3832 0.5805 
3 0.5944 0.6006 0.6165   0.6112 0.6092 0.5019 0.604 0.6135 0.3854 0.6058 
4 0.5803 0.574 0.5963 0.6175 0.6123 0.5971 0.5222 0.6276 0.6202 0.3854 0.6853 
Abs 600 
nm 
1 0.273 0.3116 0.2918 0.2787 0.3062 0.2651 0.3483 0.241 0.2587 0.5375 0.8688 
2 0.2759 0.3109 0.2851 0.2317 0.2766 0.2595 0.3699 0.2223 0.2117 0.5348 0.833 
3 0.2747 0.2849 0.2891 0.2665 0.248 0.241 0.3601 0.2411 0.2234 0.5394 0.8676 
4 0.2728 0.2915 0.2809 0.2273 0.2323 0.241 0.339 0.2229 0.2195 0.5385 0.8384 
% 
reduced 
of ctrl 
1 87.11 74.83 83.88 83.15 74.91 87.41 72.54 95.84 89.69 3.40  
2 87.21 77.15 85.91 100.23 83.67 90.36 69.77 102.23 106.27 3.47  
3 86.97 86.80 89.59   94.51 95.11 54.54 93.98 98.63 3.12  
4 88.22 83.92 90.56 103.60 101.66 96.90 64.95 106.55 105.41 3.41  
Avg  87.38 80.67 87.49 95.66 88.69 92.45 65.45 99.65 100.00 3.35  
Std 0.57 5.62 3.13 10.96 11.79 4.35 7.92 5.80 7.68 0.15  
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D.2 BSA assay calculations and data 
 
The total protein concentration in cell samples can be deducted from a BCA standard curve. The concentrations used for this experiment was 
prepared as given in table 4 (volumes adjusted to number of samples): 
 
Figure 3 BSA standard curve, absorbance plot against BSA concentration (0-2000 ug/mL). 
Calculation of total cellular protein was done by subtracting the blank measurements and adjusting for lysis volume used followed by division of 
slope from std curve ( y-value given in figure 3) 
 
eg.     abs-blank/Y*0.01 
       = 0.148-0.096/0.0013*0.01  
       = 0.064 ug protein/mL cell lysate 
 
y = 0.0013x
0.00
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1.00
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0 500 1000 1500 2000 2500
A
b
s
 (
5
7
0
n
m
)
conc (ug/mL)
Vial  Lysis 
buffer 
BSA source Conc Abs (570nm) 
A 0 uL 300 uL stock solution 2,000 ug/mL 3.065 
B 125 uL 375 uL stock solution 1,500 ug/mL 2.177 
C 325 uL 325 uL stoc solution 1000 ug/mL 1.217 
D 175 uL 175 uL from vial B 750 ug/mL 0.807 
E 325 uL 325 uL from vial C 500 ug/mL 0.482 
F 325 uL 325 uL from vial E 250 ug/mL 0.246 
G 325 uL 325 uL from vial F 125 ug/mL 0.214 
H 400 uL 100 uL from vial G 25 mg/mL 0.124 
I 400 uL 0 uL 0 mg/mL 0.096  
Table 6.1 Dilution series of BSA stock solution for standard 
curve. 
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Table 9.1 Raw and calculated absorbance data for five-day BSA assay experiment on H1299 cells. 
 
 
Time  24 hrs 48 hrs 72 hrs 
Sample C200 C200 C200 
(N) 
siRNA R-
MAX 
Ctrl C200 C200 C 200 
(N) 
siRNA R-
MAX 
Ctrl C200 C200 C 200 
(N) 
siRNA R-
MAX 
Ctrl 
N/P 10 60 60 - - - 10 60 60 - - - 10 60 60 - - - 
Parallell                                     
R
a
w
 d
a
ta
  1 0.105 0.105 0.102 0.104 0.106 0.107 0.242 0.253 0.241 0.237 0.233 0.234 0.409 0.394 0.403 0.382 0.322 0.391 
2 0.101 0.103 0.101 0.103 0.107 0.104 0.226 0.220 0.220 0.226 0.219 0.239 0.450 0.362 0.395 0.410 0.364 0.418 
3 0.104 0.104 0.102 0.104 0.104 0.114 0.225 0.225 0.233 0.232 0.218 0.231 0.384 0.413 0.391 0.362 0.359 0.363 
4 0.104 0.104 0.102 0.104 0.106 0.112 0.194 0.204 0.189 0.195 0.179 0.190 0.398 0.417 0.373 0.383 0.382 0.379 
B
la
n
k
 
s
u
b
tr
a
c
te
d
 1 0.008 0.008 0.006 0.008 0.010 0.011 0.145 0.157 0.144 0.141 0.137 0.137 0.313 0.297 0.306 0.285 0.226 0.294 
2 0.005 0.006 0.005 0.006 0.010 0.008 0.130 0.123 0.123 0.129 0.123 0.142 0.353 0.266 0.298 0.313 0.268 0.321 
3 0.008 0.007 0.005 0.007 0.008 0.017 0.128 0.128 0.137 0.136 0.122 0.134 0.287 0.316 0.295 0.266 0.263 0.266 
4 0.007 0.008 0.006 0.007 0.010 0.015 0.097 0.108 0.093 0.098 0.082 0.093 0.301 0.320 0.276 0.286 0.286 0.282 
D
iv
id
e
d
 b
y
 
s
lo
p
e
  
1 0.064 0.065 0.044 0.061 0.076 0.083 1.116 1.206 1.111 1.082 1.053 1.057 2.405 2.286 2.357 2.193 1.735 2.263 
2 0.036 0.046 0.037 0.046 0.079 0.061 0.998 0.947 0.949 0.993 0.943 1.094 2.719 2.046 2.293 2.410 2.060 2.469 
3 0.059 0.056 0.040 0.056 0.058 0.132 0.988 0.986 1.053 1.042 0.936 1.032 2.209 2.434 2.266 2.043 2.019 2.048 
4 0.056 0.059 0.043 0.056 0.073 0.118 0.746 0.830 0.713 0.756 0.634 0.719 2.318 2.462 2.126 2.203 2.198 2.170 
Avg 
prot/mL 
cell lys  
0.054 0.056 0.041 0.055 0.072 0.098 0.962 0.992 0.956 0.968 0.891 0.976 2.412 2.307 2.261 2.212 2.003 2.238 
Std  
prot/mL 
cell lys 
0.012 0.008 0.003 0.006 0.010 0.032 0.155 0.157 0.176 0.147 0.180 0.173 0.219 0.191 0.097 0.151 0.194 0.178 
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Table 9.2 Raw and calculated absorbance data for five-day BSA assay experiment on H1299 cells. 
 
Time  96 hrs 120hrs 
Sample C200 C200 C 200 (N) siRNA R-MAX Ctrl C200 C200 C 200 (N) siRNA R-MAX Ctrl 
N/P 10 60 60 - - - 10 60 60 - - - 
  Parallell                          
R
a
w
 d
a
ta
 1 0.463 0.481 0.513 0.479 0.426 0.516 0.495 0.468 0.504 0.508 0.527 0.513 
2 0.449 0.444 0.510 0.606 0.483 0.485 0.397 0.513 0.561 0.486 0.419 0.469 
3 0.524 0.493 0.482 0.560 0.461 0.484 0.511 0.518 0.528 0.453 0.492 0.701 
4 0.507 0.500 0.536 0.511 0.583 0.456 0.389 0.466 0.504 0.495 0.454 0.507 
B
la
n
k
 
s
u
b
tr
a
c
te
d
 1 0.367 0.384 0.417 0.383 0.330 0.420 0.398 0.372 0.408 0.411 0.431 0.417 
2 0.353 0.347 0.414 0.510 0.386 0.388 0.300 0.417 0.464 0.389 0.322 0.372 
3 0.428 0.396 0.385 0.463 0.364 0.388 0.414 0.422 0.432 0.357 0.396 0.604 
4 0.410 0.403 0.439 0.414 0.486 0.360 0.292 0.370 0.408 0.399 0.357 0.411 
D
iv
id
e
d
 b
y
 
s
lo
p
e
 +
 l
y
s
a
te
 
a
d
ju
s
tm
e
n
t 1 2.821 2.956 3.206 2.943 2.536 3.229 3.064 2.861 3.137 3.165 3.312 3.207 
2 2.715 2.672 3.183 3.922 2.971 2.985 2.308 3.207 3.572 2.995 2.477 2.862 
3 3.289 3.046 2.965 3.562 2.802 2.982 3.186 3.244 3.321 2.743 3.045 4.648 
4 3.157 3.103 3.380 3.188 3.742 2.766 3.122 2.844 3.135 3.068 2.748 3.158 
Avg protein/mL cell lysate  2.995 2.944 3.183 3.404 3.012 2.990 2.853 3.039 3.291 2.993 2.896 3.469 
STDEV protein/mL cell 
lysate 
0.272 0.192 0.170 0.429 0.518 0.190 0.476 0.216 0.207 0.180 0.362 0.801 
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D.3 Cell count data 
 
Table 10. Estimated raw data for cellular proliferation in H1299 cells over 5-days after counting with bürker chambers.   
 
Time 24hrs 48hrs 
Sample C200 C200 C 200 (N) siRNA R-MAX Ctrl C200 C200 C 200 (N) siRNA R-MAX Ctrl 
N/P 10 60 60       10 60 60       
Cell 
count 
Parallell                         
1 9000 6750 7650 8550 6300 10350 15000 10500 11700 14700 9000 16500 
2 9450 5850 8100 9000 5400 11250 14400 9600 11400 14100 8700 17400 
Avg 9225 6300 7875 8775 5850 10800 14700 10050 11550 14400 8850 16950 
Std 318.198 636.396 318.198 318.198 636.396 636.396 424.264 636.396 212.132 424.264 212.132 636.396 
  
Time 72hrs 96hrs 
Sample C200 C200 C 200 (N) siRNA R-MAX Ctrl C200 C200 C 200 (N) siRNA R-MAX Ctrl 
N/P 10 60 60       10 60 60       
Cell 
count 
Parallell                         
1 29700 21600 22800 30000 18000 32400 45000 33000 33900 44700 29700 48000 
2 29100 21000 22500 28800 19200 33600 43500 33600 34500 46500 29100 49200 
Avg 29400 21300 22650 29400 18600 33000 44250 33300 34200 45600 29400 48600 
Std 424.264 424.264 212.132 848.528 848.528 848.528 1060.660 424.264 424.264 1272.792 424.264 848.528 
  
Time 120hrs 
Sample C200 C200 C 200 (N) siRNA R-MAX Ctrl 
N/P 10 60 60       
Cell 
count 
Parallell             
1 48600 35400 35100 48300 30600 51300 
2 49800 35700 36000 48000 30300 52500 
Avg 49200 35550 35550 48150 30450 51900 
Std 848.528 212.132 636.396 212.132 212.132 848.528 
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D.4  PI staining flow cytometry data 
 
Table 11.1 Raw and calculated  flow cytometry data for 5-days PI staining experiment. 
 
 
 
 
Time 24hrs 48hrs 
Sample C200 C200 C 200 
(N) 
siRNA R-MAX Ctrl C200 C200 C 200 
(N) 
siRNA R-MAX Ctrl 
N/P 10 60 60 - - - 10 60 60 - - - 
  Parallell                         
Median FI 1 2.06 5.99 7.66 7.19 9.3 4.79 7 10.71 11.98 8.88 22.95 4.89 
2 2.17 8.04 10.55 8.68 9.62  * 7.15 7.51 14.98 8.89 23.37  * 
%of ctrl 1 43.01 125.05 159.92 150.10 194.15 100.00 143.15 219.02 244.99 181.60 469.33 100.00 
2 45.30 167.85 220.25 181.21 200.84  * 146.22 153.58 306.34 181.80 477.91  * 
Average 44.15 146.45 190.08 165.66 197.49 100.00 144.68 186.30 275.66 181.70 473.62 100.00 
STDEV 1.62 30.26 42.66 22.00 4.72 0.00 2.17 46.27 43.38 0.14 6.07 0.00 
                            
Time 72hrs 96hrs 
Sample C200 C200 C 200 
(N) 
siRNA R-MAX Ctrl C200 C200 C 200 
(N) 
siRNA R-MAX Ctrl 
N/P 10 60 60 - - - 10 60 60 - - - 
  Parallell                         
Median FI 1 6.32 17.55 16.54 18.34 34.06 4.95 3.37 6.53 6.28 15.23 16.66 5.24 
2 15.83 15.9 17.18 9.1 31.26 6.7 5.56 6.46 7.27 9.78 16.5 5.11 
%of ctrl 1 108.5 301.29 283.9 314.8 584.721 84.979 231.3 303.57 175.1 242.5121 310.5314 101.3 
2 271.76 272.96 294.9 156.2 536.6524 115.02   198.45 176.2 231.3043 297.971 98.74 
Average 190.13 287.12 289.4 235.5 560.6867 100 231.3 251.01 175.7 236.9082 304.2512 100 
STDEV 115.44 20.03 7.769 112.2 33.98968 21.244 0 74.332 0.82 7.925062 8.881534 1.776 
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Table 11.2 Raw and calculated flow cytometry data for 5-days PI staining experiment. 
 
 
 
 
 
 
 
 
 
 
Time 120hrs 
Sample C200 C200 C 200 (N) siRNA RNAiMAX Ctrl 
N/P 10 60 60 - - - 
  Parallell             
Median 
FI 
1 11.97 15.71 9.06 12.55 16.07 4.99 
2 * 10.27 9.12 11.97 15.42 * 
%of ctrl 1 239.88 314.83 181.563126 251.5 322.0441 100 
2 0 205.81 182.765531 239.9 309.018 * 
Average 239.88 260.32 182.164329 245.7 315.5311 100 
STDEV 0 77.087 0.85022859 8.219 9.21081 0 
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E Rho 123 efflux data  
 
E.1 mdr1 downregulation  in RBE4 cells  
 
Table 11 Raw and calculated flow cytometry data for Rho 123 efflux in RBE4 cells  
 
Sample C 300 T C 300 T C 300 NT C 400 T C 400 T C 400 NT siRNA ctrl ctrl + 
Verapamil 
N/P 10 10 10 10 10 10 - - 10 uM 
siRNA mdr1a mdr1b   mdr1a mdr1b   mdr1a -  
  Parallell                   
Median FI 1 6.19 3.01 3.45 6.19 3.3 4.05 3.15 3.84 42.4 
2 7.21 3.27 3.12 6.02 3.77 3.18 3.18 2.41 68.3 
3 7.08 3.27 2.96 5.49 3.88 4.02 3.07 2.52 49 
% of 
Verapamil 
ctrl 
1 11.15 5.42 6.21 11.15 5.94 7.29 5.67 6.92 76.36 
2 12.99 5.89 5.62 10.84 6.79 5.73 5.73 4.34 123.01 
3 12.75 5.89 5.33 9.89 6.99 7.24 5.53 4.54 88.25 
avg 12.07 5.66 5.92 11.00 6.37 6.51 5.70 5.63 100.00 
stdev 1.30 0.33 0.42 0.22 0.60 1.11 0.04 1.82 21.44 
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Figure 7. Rho123 acumulation in RBE4 cells, untreated control 
 
 
Figure 8. Rho123 accumuation in RBE4 cells treated with chitosan DPn300 complexed with mdr1a-siRNA at N/P ratio 10 
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E.2 Verapamil  and siRNA concenctration effect on Rho123 efflux  
 
Table 13. Raw and calculated flow cytometry data for temporal Verapamil concentration dependent Rho123 efflux in RBE4 cells. 
 
Time 1hrs 1,5 hrs 
Concentration   0uM 5uM 10uM 25um 50uM 250uM 0uM 5uM 10uM 25um 50uM 250uM 
  Parallell                         
Median FI 1 152 224 234 218 512 708 72 64.7 81  * 357 566 
2 156 268 182 280 424 768 68.3 79.6 139 139 348 636 
3 139 293 230 315 464 768 63 101 155 155  *  * 
avg 149.00 261.67 215.33 271.00 468.00 738.00 67.77 81.77 125.00 147.00 352.50 601.00 
std 8.89 34.93 28.94 49.12 62.23 42.43 4.52 18.25 38.94 11.31 6.36 49.50 
                
Time 2hrs 
Concentration   0uM 5uM 10uM 25um 50uM 250uM 
  Parallell             
Median FI 1  *  *  *  *  *  * 
2 65.9 87.9 121 158 216 470 
3  *  * 78.2  * 377  * 
avg 65.90 87.90 99.60 158.00 296.50 470.00 
std 0.00 0.00 30.26 0.00 113.84 0.00 
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Table 14 Raw and calculated flow cytometry data for Verapamil concentration dependent Rho123 efflux in RBE 4 cells  
 
Concentration 0uM 5uM 10uM 25um 50uM 250uM 
  Parallell             
Median FI 1 3.88 256 293 381 428 571 
2 4.36 304 299 402 455 608 
3 3.95 299 374 440  * 636 
avg 4.06 286.33 322.00 407.67 441.50 605.00 
std 0.26 26.39 45.13 29.91 19.09 32.60 
 
Table 15 Raw flow cytometry data for siRNA concentration dependent Rho123 efflux I RBE4 cells. 
 
Sample C500  C500 
NT 
C500  C500 
NT 
C500  C500 
NT 
C500  C500 
NT 
C500  C500 
NT 
C500  C500 
NT 
vera ctrl 
Conc (nM) 96 96 48 48 24 24 12 12 6 6 3 3 -   
Median FI 1 28.9 4.24 16.8 3.27 10.7 3.36 6.71 4.68 5.55 4.52 4.17 4.4 5.26 3.91 
2 * 4.77 24.7 3.24 13.5 3.33 6.24 5.46 5.03 4.85 4.2 4.68 5.97 4.52 
3 * 4.48 19.90 3.36  * 3.27 5.46 4.48 6.36 4.44 4.90 3.67  * 3.4 
avg 28.9 4.5 20.5 3.3 12.1 3.3 6.1 4.9 5.6 4.6 4.4 4.3 5.6 3.9 
std 0 0.265 3.980 0.062 1.980 0.046 0.631 0.518 0.670 0.217 0.413 0.521 0.502 0.566 
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